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DNP-SG S-(2,4-dintriphenyl)-glutathione 
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1 SUMMARY 
Organic anion transporting polypeptides (OATPs) have been identified as Na+-
independent transport system for bile acids in rat and human liver. Until their discovery 
in the 1990s members of this transporter family were found to be present in various 
species, including mouse, rat, cow, horse, and quail. In humans, eleven OATP family 
members are known so far, which are classified based on their amino acid sequence 
homology into families and subfamilies. The human OATP-family occurs in a variety of 
different tissues, including liver, kidney, intestine, and brain. While some of them are 
ubiquitously expressed, others show a rather narrow expression pattern, like the 
OATP1B family members, OATP1B1 and 1B3, which are exclusively present in the 
basolateral membrane of hepatocytes in human liver, and OATP4C1 which has only 
been identified in the kidney. OATPs have been described to mediate the transport of 
endogenous compounds as well as xenobiotics, although only the members of the 
OATP1 family and OATP2B1 are one of the best-characterized OATPs concerning their 
substrate specificity. Until now no systematic studies are available, characterizing the 
substrate specificity of all known human OATPs. Furthermore, the requirements for 
molecules transported via the OATP family are not totally clarified. Presently, OATP 
substrates are defined as anionic amphipathic organic compounds with a high 
molecular weight (>450 Da), although neutral and cationic compounds have also been 
identified as OATP substrates. Bile acids and steroid/ thyroid hormones including their 
conjugates are typical endogenous OATP substrates. In addition, several clinically used 
drugs have been characterized as OATP substrates, including antibiotics, statins, and 
antihypertensives. Based on their localization and their function as uptake transporters 
OATPs play a critical role in the absorption, disposition and excretion of xenobiotics. 
Although some anticancer agents have been reported to be mediated via OATPs, the 
knowledge on the role of these transporters in malignancies is limited. 
Therefore, the aim of this thesis was to identify the expression pattern of the human 
OATP family in selected cancer diseases. First the occurrence of OATP family 
members in breast cancer tissues was investigated. Real-time PCR analysis was 
performed for tissue samples derived from 13 patients, showing mRNA expression of 
six OATPs in this malignancy. Adjacent non-malignant samples were chosen as normal 
control, as it is known that expression pattern of transporter proteins show high 
interindividual variability as result of genetic, environmental and physiological factors. 
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Indeed, in the majority of investigated specimens clear differences were observed in the 
mRNA expression comparing malignant and non-malignant specimens, with higher 
mRNA levels in the non-malignant control samples. In addition, interindividual 
alterations in OATP expression were detected, indicating a possible role of these 
transporters in altered uptake rates of anticancer agents into tumor cells. OATPs in 
breast cancer may not only be important for the uptake of anticancer drugs into tumor 
cells, but also for the uptake of estrone-3-sulfate. This is of special interest as sulfatases 
in estrogen-dependent breast tumors are able to convert inactive estrone-3-sulfate into 
active estrogen. Contrary, the family of sulfotransferases (SULTs) can convert estrogen 
back into the inactive sulfated form. Therefore, the presence of three sulfatases (STS, 
ARS-B, ARS-A) and four sulfotransferases (SULT1A1, 1A2, 1A3, 1E1) was investigated 
in breast cancer tissue samples and their adjacent non-malignant specimens by real-
time PCR analysis. Similar mRNA expression levels were revealed for the 
sulfotransferase family members SULT1A2, 1A3, and 1E1 comparing tumorous and 
non-malignant tissue samples. However, SULT1A1 expression was below the detection 
limit in all samples. Regarding mRNA expression of investigated sulfatases, steroid 
sulfatase (STS) showed higher mRNA levels in non-malignant specimens than in tumor 
tissue samples. Neither for arylsulfatases ARS-A nor for ARS-B, any differences in 
mRNA expression between malignant and non-malignant samples could be detected. 
Paclitaxel, an anticancer drug used in the treatment of metastatic breast cancer, has 
been investigated as possible substrate for the liver-specific OATP1B1 and 1B3, 
identifying OATP1B3 as high affinity transporter for paclitaxel. Regarding our mRNA 
expression analysis in breast cancer tissues, this OATP family member could not be 
detected in the investigated specimens. However, as OATPs are known to exhibit 
overlapping substrate specificity, an involvement of other OATP family members in the 
transport of paclitaxel was suggested. Therefore, the present work initiated the first 
systematic characterization of all known human OATPs for their ability to transport 
paclitaxel. Thus, full length cRNAs for all eleven OATP family members were generated 
and injected into Xenopus laevis oocytes. OATP expressing oocytes were then 
incubated with radiolabeled paclitaxel for an initial time of 60 min, showing paclitaxel 
transport activity for OATP1B1 and 1B3. For all other nine OATP family members 
paclitaxel exhibited no substrate activity. Kinetic analysis of OATP1B1 and 1B3 
mediated paclitaxel transport revealed Km values of 0.6 µM and 1.6 µM, respectively, 
identifying OATP1B1 as additional high affinity paclitaxel transporter.  
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Beside paclitaxel, methotrexate has been previously identified as substrate for 
OATP1A2. As this agent is used in the chemotherapy regimen of osteosarcomas and 
OATPs have not been investigated in this disease until now, the present thesis further 
show investigations on OATP distribution in bone tumors. Bone tumor specimens from 
21 patients as well as cell lines derived from osteosarcomas (HOS and MG-63), normal 
human osteoblasts outgrowth cells (hOB) and bone marrow stromal cells (BMSC) were 
examined concerning mRNA expression pattern of all eleven human OATP family 
members by real-time PCR analysis. With the exception of the liver-specific OATP1B1 
and 1B3 and the testes specific OATP6A1, all other members of this transporter family 
could be detected in the specimens investigated. However, the cell lines only exhibited 
detectable mRNA levels of OATP3A1 and 4A1. 
The liver is known to play a key role in metabolism and elimination. The identification 
and localization of OATPs in the basolateral membrane of hepatocytes and their ability 
to mediate a broad spectrum of endogenous and exogenous compounds allows a more 
detailed insight and understanding for the physiologic function of the human liver but 
also for the occurrence of side effects in therapies. Although the role of OATPs in 
human liver is well studied, the knowledge of their expression pattern in liver 
malignancies is limited or focused on the expression of OATP1B3 and 1B1 in 
hepatocellular carcinoma. Therefore, the presence of all known OATP family members 
in liver malignancies of 22 patients was examined using real-time PCR. To clarify 
possible changes in mRNA expression between normal controls and tumors, again the 
adjacent non-malignant tissues of the same patients were included in real-time PCR 
analysis. With the exception of OATP6A1 and 1C1, which were only present in a 
minority of specimens, all other OATPs showed detectable mRNA expression. 
Interestingly, OATP1B1, 1B3, 2B1, 1A2, and 4C1 showed decreased mRNA levels in 
the malignant samples compared to the adjacent non-malignant controls. Otherwise, 
mRNA of OATP2A1, 3A1, 4A1, and 5A1 were increased in the malignant samples. 
Beside hepatocellular carcinomas, cholangiocarcinomas and liver metastases derived 
from tumors of other organs are also frequent malignant diseases. Therefore, the 
specimens investigated derived from these different types of liver malignancies. Indeed 
differences in mRNA expression pattern of present OATPs between hepatocellular-, 
cholangiocarcinomas and liver metastases were observed.  
Summarized, various OATPs were identified to be present in bone, breast, and liver 
malignancies, showing interindividual mRNA expression differences and altered 
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expression pattern compared to non-malignant controls. These findings indicate a 
possible role of this transporter family in response rate variation of anticancer therapy 
when using drugs which are OATP substrates. 
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2 ZUSAMMENFASSUNG 
Organische Anionen transportierende Polypeptide (OATPs) wurden als Natrium-
unabhängige Transportsysteme für Gallensäuren in der Ratten- und Menschenleber 
identifiziert. Seit ihrer Entdeckung in den 90er Jahren wurde ihr Vorkommen in den 
verschiedensten Spezies nachgewiesen. Im Menschen konnten bisher elf verschiedene 
OATPs identifiziert werden, die nach ihrer Homologie in der Aminosäuresequenz in 
Familien und Unterfamilien eingeteilt werden und bisher in einer Vielzahl von Geweben 
nachgewiesen werden konnten. Während manche dieser OATPs in unterschiedlichen 
Geweben vertreten sind, zeigen andere, wie etwa OATP1B1 und 1B3 die bis dato nur in 
der Leber identifiziert wurden, Gewebsspezifität. OATP4C1 hingegen konnte nur in der 
Niere nachgewiesen werden. Die Familie der OATPs ist für die Aufnahme von 
endogenen als auch exogenen Substanzen in die Zelle verantwortlich. Bis heute 
wurden jedoch nur einige wenige Mitglieder dieser Transporterfamilie hinsichtlich ihrer 
Substratspezifität charakterisiert. Weiters sind die Voraussetzungen, welche eine 
Substanz erfüllen muss um von OATPs als Substrat transportiert zu werden, noch nicht 
vollständig geklärt. Bisherige Untersuchungen haben gezeigt, dass amphipathische, 
organische Anionen mit hohem Molekulargewicht (>450 Da) aber auch neutrale sowie 
kationische Substanzen Substrate von OATPs sind. Als typische Substrate wurden 
Gallensäuren, Steroid-/ Thyroidhormone sowie deren Konjugate identifiziert. Zu den 
Arzneistoffen, die als OATP Substrate gelten, gehören Vertreter der Antibiotika, 
Cholesterinsenker oder Antihypertensiva. Basierend auf ihrer Lokalisation im 
menschlichen Körper und ihrer Funktion als Aufnahmetransporter spielen OATPs eine 
wichtige Rolle in der Absorption, Disposition und Elimination von exogenen Substanzen. 
Obwohl schon bekannt ist, dass auch Zytostatika zu den OATP Substraten zählen, ist 
das Wissen über deren Rolle in malignen Tumoren limitiert. Aus diesem Grund war es 
Ziel dieser Dissertation, die Expression der OATP Familie in ausgesuchten Tumorarten 
zu untersuchen. Erst wurde mittels real-time PCR das Vorkommen aller elf im 
Menschen identifizierten OATPs in Brustkrebsgewebeproben von 13 Patientinnen 
untersucht. Sechs der elf bekannten OATPs konnten auf mRNA Ebene in diesen 
Proben nachgewiesen werden. Weiters sollte festgestellt werden, ob ein Unterschied in 
der mRNA Expressionsrate zwischen Normal- und Tumorgewebe besteht. Dazu wurde 
zu jeder der untersuchten Tumorproben das Normalgewebe derselben Patientin, 
welches aus dem sogenannten Resektionsrand entnommen wurde, als Kontrolle 
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untersucht. Es ist von großer Bedeutung, eine Probe derselben Patientin als 
Kontrollgewebe zur Verfügung zu haben, da das Expressionsmuster von Proteinen 
durch genetische, physiologische und umweltbedingte Faktoren interindividuell sehr 
unterschiedlich ausgeprägt sein kann. Wie erwartet konnte ein deutlicher Unterschied in 
der Expression der sechs präsenten OATPs zwischen malignem und normalem 
Gewebe festgestellt werden. In der Mehrzahl der untersuchten Tumorproben konnten 
höhere mRNA Raten verglichen mit dem Normalgewebe gezeigt werden. Weiters 
offenbarte sich auch eine große interindividuelle Schwankung in der Expression. Diese 
Ergebnisse weisen darauf hin, dass eine unterschiedliche Expression dieser 
Aufnahmetransporter für unterschiedliche Akkumulationsraten von Chemotherapeutika 
verantwortlich sein könnte. Weiters spielen OATPs eine wichtige Rolle bei der 
Aufnahme von Östron-3-sulfat, einem typischen Substrat dieser Transporterfamilie. 
Dies ist von besonderem Interesse, da für viele Brusttumore eine Östrogenabhängigkeit 
nachgewiesen wurde. Diese Tumore sind in der Lage, aufgenommenes Östron-3-sulfat 
mittels Sulfatasen in aktives Östrogen umzuwandeln. Hingegen können Enzyme der 
Familie der Sulfotransferasen aktives Östrogen wieder in die inaktive Ausgangsform 
Östron-3-sulfat konvertieren. Daher wurde weiters die mRNA Expression sowohl von 
Sulfatasen als auch Sulfotransferasen in malignen und korrespondierenden normalen 
Gewebeproben von Patientinnen mit Brustkrebs mittels real-time PCR untersucht. Drei 
der vier untersuchten Sulfotransferasen (SULT1A2, 1A3, 1E1) zeigten ähnliche mRNA 
Expressionsraten im Tumorgewebe verglichen mit dem Normalgewebe. SULT1A1 
hingegen konnte weder im Normal- noch im Tumorgewebe nachgewiesen werden. 
Interessanterweise konnten für die Steroidsulfatase wesentlich höhere mRNA 
Expressionsraten im untersuchten Normalgewebe verglichen mit den Tumorproben 
gezeigt werden. Die beiden Arylsulfatasen A und B hingegen wiesen keinen 
Unterschied in ihren mRNA Expressionen zwischen malignen und nichtmalignen 
Proben auf. 
Paclitaxel, ein in der Therapie von metastasierendem Brustkrebs häufig eingesetztes 
Zytostatikum, wurde hinsichtlich seiner Substrateigenschaften bisher nur für die 
leberspezifischen OATP Familienmitglieder- OATP1B1 und 1B3- untersucht. Diese 
Studie charakterisierte Paclitaxel als Substrat für OATP1B3. In den Untersuchungen 
dieser Dissertation zeigte sich allerdings, dass OATP1B3 in den getesteten 
Brusttumorproben nicht vorkommt. Da aber eine überlappende Substratspezifität der 
einzelnen OATP Familienmitglieder bekannt ist, liegt es nahe, dass auch andere 
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Mitglieder der OATP Familie als Transportproteine für Paclitaxel fungieren könnten. 
Deshalb wurden erstmals die Transporteigenschaften aller im Menschen bekannten 
OATPs für Paclitaxel charakterisiert. Für diese Untersuchung wurden cRNAs aller elf 
OATPs generiert und in Oozyten des südafrikanischen Krallenfrosches (Xenopus 
laevis) injiziert. Erst wurde die Aufnahme von radioaktiv markiertem Paclitaxel in den 
OATP exprimierenden Oozyten nach einer Inkubation von 60 Minuten untersucht. Diese 
zeigte, dass neben OATP1B3 auch OATP1B1 eine deutliche Transportaktivität für 
Paclitaxel aufweist. Für die restlichen der elf OATPs konnte kein Paclitaxeltransport 
festgestellt werden. Der OATP1B1- und OATP1B3-vermittelte Paclitaxeltransport wurde 
ebenfalls hinsichtlich seiner Kinetik charakterisiert und beschrieb eine 2.5-fach höhere 
Affinität von Paclitaxel zu OATP1B1 (Km OATP1B1: 0.6 µM; Km OATP1B3: 1.6 µM).  
Neben Paclitaxel wurde auch Methotrexat als Substrat für OATP1A2 in vorhergehenden 
Studien identifiziert. Da Methotrexat ein wichtiger Bestandteil der Standardtherapie von 
Knochentumoren ist, wurde in dieser Dissertation auch die Expression von OATPs in 
Osteosarkomaproben von 21 Patienten untersucht. In weiterer Folge wurden 
Osteosarkomazelllinien (HOS und MG-63) sowie nicht maligne Zelllinien (hOB und 
BMSC) in die real-time PCR Analysen miteinbezogen. Mit Ausnahme der 
leberspezifischen Transporter OATP1B1 und 1B3 und des testisspezifischen OATP6A1, 
konnten alle anderen der elf bekannten OATPs in den Osteosarkomaproben 
nachgewiesen werden. In den Zelllinien hingegen war eine mRNA Expression nur für 
OATP3A1 und 4A1 nachweisbar.  
Die Leber spielt eine wichtige Rolle in der Metabolisierung und Eliminierung endogener 
wie exogener Substanzen. Die Identifizierung und Lokalisierung von OATPs in der 
basolateralen Membran der Hepatozyten und deren Funktion als Aufnahmetransporter 
für eine Vielzahl von endo- und exogenen Stoffen ermöglicht uns ein besseres 
Verständnis der physiologischen Funktion dieses Organs aber auch der Ursachen von 
Interaktionen oder toxischen Nebenwirkungen von Arzneistoffen. Obwohl die Rolle der 
OATPs in der normalen, gesunden Leber gut untersucht ist, ist ihre Bedeutung in 
malignen Erkrankungen dieses Organs noch nicht vollständig geklärt beziehungsweise 
konzentrierten sich bisherige Untersuchungen auf die Expression der beiden 
leberspezifischen OATPs, OATP1B1 und 1B3, vor allem im hepatozellulärem Karzinom. 
Aus diesem Grund wurden abermals real-time PCR Analysen in 
Lebertumorgewebeproben von 22 Patienten durchgeführt und das Vorkommen der 
mRNA aller humanen OATPs untersucht. Auch bei dieser Studie wurden die nicht 
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malignen Gewebeproben derselben Patienten als Kontrolle in die mRNA 
Expressionsanalyse miteinbezogen. Mit der Ausnahme von zwei OATP-
Familienmitgliedern- OATP6A1 und 4C1- konnte die mRNA aller im Menschen bisher 
bekannten OATPs nachgewiesen werden. Interessant war, dass fünf dieser OATPs 
(OATP1B1, 1B3, 2B1, 1A2, 4C1) geringere mRNA Expressionsraten in den malignen 
Gewebeproben, verglichen mit den jeweiligen Kontrollen, zeigten. Hingegen wurde für 
die anderen vier OATP Familienmitglieder eine erhöhte mRNA Expression in den 
malignen Gewebeproben festgestellt. Da neben dem hepatozellulären Karzinom sowohl 
Cholangiokarzinome als auch Lebermetastasen anderer Tumore weitverbreitete 
Erkrankungen darstellen, deckten die in dieser Arbeit untersuchten Gewebeproben alle 
drei Arten maligner Erkrankungen der Leber ab. Dadurch konnten auch mögliche 
Unterschiede im Expressionsmuster zwischen diesen verschiedenen Tumorarten 
untersucht und festgestellt werden.  
Zusammenfassend konnte in der vorliegenden Arbeit das Vorhandensein von 
Mitgliedern der OATP Transporterfamilie in Tumorgeweben der Brust, des Knochens 
und der Leber nachgewiesen werden. Das Expressionsmuster auf mRNA Ebene zeigte 
nicht nur deutliche interindividuelle Unterschiede sondern auch veränderte 
Expressionsmuster in malignen Geweben. Diese Ergebnisse weisen auf eine wichtige 
Rolle der OATPs in Krebszellen hin, da unterschiedliche Expressionsraten ein Grund für 
interindividuell schwankende Ansprechraten auf Chemotherapien mit Zytostatika, die 
OATP Substrate sind, sein könnten. 
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3 INTRODUCTION 
3.1 Organic Anion Transporting Polypeptides (OATPs) 
3.1.1 History of discovery 
In hepatocytes, transmembrane transport of organic anions, e.g. bile acids, bilirubin-
glucuronide, and bromosulfophthalein has been shown to be mediated by Na+-
dependent and -independent transport systems.1,2 One year after the characterization of 
the Na+-dependent taurocholate cotransporting polypeptide (Ntcp) in mammalian liver in 
1993,3 the first member of a Na+-independent transport system, the so-called Oatp 
family (Oatp1a1), could be identified after cloning of the transporter from a rat liver 
cDNA library. The transporter was characterized by size-fractioning and was expressed 
in Xenopus laevis oocytes for transport studies.4 In 1995, the first human OATP family 
member, OATP1A2, was identified in human liver.5 Since these early descriptions, 
genome-sequencing projects predict the existence of more than 160 OATPs/Oatps in 
about 25 animal species. However, only few of these putative transporters were 
structurally and functionally characterized until now.6 In humans, eleven OATP family 
members have been identified so far.7  
3.1.2 Classification and nomenclature 
Since the discovery of the first OATP/Oatp family member, a number of OATPs/Oatps 
have been identified in humans and different animal species including rat, mouse,8,9 
cow10, horse11, and quail.12 The identification of more and more OATP/Oatp family 
members by different groups, the use of various arbitrary names and the lack of 
consistent nomenclature resulted in confusion. Furthermore, the old classification 
system led to difficulties in the differentiation between OATPs/Oatps of different 
species, as sometimes the same name was accidently assigned for different family 
members in different species (rOatp1/ hOATP1 or rOatp2/mOatp2/hOATP2).8 
To reach clarification, Hagenbuch and Meier (2004) established a species-independent 
and open-ended nomenclature, based on the classification system used for the 
cytochrome P450 family. This new nomenclature was approved by the HUGO Gene 
Nomenclature Committee (Table 1). Based on the amino acid sequences, the 
OATP/Oatp superfamily is divided into six families consisting of up to four subfamilies 
(Figure 1).The six OATP/Oatp families - OATP1, OATP2, OATP3, OATP4, OATP5, and 
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OATP6 - are designated by numbers from 1 to 6. Each family is characterized by an 
amino sequence homology of more than 40%. The members of the same subfamily 
show an amino acid sequence identity of more than 60%. Every subfamily is designated 
by a letter from A to D and followed by an additional numbering for each individual 
member. To facilitate differentiation between human and rodent members of this 
transporter family, the classification system provides designation of human OATP/SLCO 
proteins/genes by capitals (e.g. OATP1A2/SLCO1A2), while those of rat and mouse are 
given in small letters with an initial capital (e.g. Oatp1a1/Slco1a1). In this new 
nomenclature, the symbol “SLCO” is selected for gene classification, while the old 
protein symbol “OATP” is kept for the corresponding protein nomenclature.8 
Table 1 New and old gene and protein nomenclature (modified from Hagenbuch and Meier 2004)8 
 New Gene 
Name   
Old Gene 
Name   
New Protein 
Name   
Old Protein 
Names   
 SLCO1A2 
 
SLC21A3 
 
OATP1A2 
 
OATP-A, OATP 
 
 SLCO1B1 
 
SLC21A6 
 
OATP1B1 
 
OATP-C, LST-1, OATP2 
 
 SLCO1B3 
 
SLC21A8 
 
OATP1B3 
 
OATP8, LST-2 
 
 SLCO1C1 
 
SLC21A14 
 
OATP1C1 
 
OATP-F, OATP-RP5 
 
 SLCO2A1 
 
SLC21A2 
 
OATP2A1 
 
hPGT 
 
 SLCO2B1 
 
SLC21A9 
 
OATP2B1 
 
OATP-B, OATP-RP2 
 
 SLCO3A1 
 
SLC21A11 
 
OATP3A1 
 
OATP-D, OATP-RP3 
 
 SLCO4A1 
 
SLC21A12 
 
OATP4A1 
 
OATP-E, OATP-RP1 
 
 SLCO4C1 
 
SLC21A20 
 
OATP4C1 
 
OATP-H 
 
 SLCO5A1 
 
SLC21A15 
 
OATP5A1 
 
OATP-J, OATP-RP4 
 
 SLCO6A1 
  
SLC21A19 
  
OATP6A1 
  
OATP-I, GST 
  
 
In fact, all Oatps/OATPs together form a transporter gene superfamily, with homology 
between different species, resulting in a phylogenetic tree (Figure 1).8 Regarding this 
phylogenetic tree and the distribution of the 36 identified OATPs/Oatps in human, rat 
and mouse, it can be recognized that some family members show a 1:1 relationship 
between different species like the OATP3 family. However, the OATP1A family exhibit 
only one member in humans but five in rats. Likewise the OATP1B family consists of 
two human members but have only one member in rat and mouse, respectively. This 
unequal distribution of OATP/Oatp family members in-between the different species 
may be due to gene duplication events after humans and rodents diverged.13 
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Although the official nomenclature provides the differentiation of genes and proteins by 
using the terms “SLCO/Slco” or “OATP/Oatp”, respectively, I will limit myself to the use 
of the term “OATP/Oatp” throughout this thesis to simplify understanding for people who 
are not so familiar with the classification system of the OATP family. 
 
Figure 1 Phylogenetic tree of the OATP/Oatp superfamily in human and various animal species. 
b, bovine; c, chicken; h, human; m, mouse; r, rat; s, skate.6 
3.1.3 Chromosomal location and tissue distribution 
Table 2 Tissue distribution and chromosomal location of human OATPs.14 
OATP   Gene locus   Tissue distribution 
OATP1A2  12p12  Brain, kidney, liver, intestine, ciliary body 
OATP1B1  12p12  Liver 
OATP1B3  12p12  Liver 
OATP1C1  12p12  Brain, testes, ciliary body 
OATP2A1  3q21  Ubiquitous 
OATP2B1  11q13  Liver, placenta, intestine, heart, skin, pancreas, lung, colon, 
ovary, testes, kidney, spleen, skeletal muscle 
OATP3A1  15q26  Ubiquitous 
OATP4A1  20q13.1  Ubiquitous 
OATP4C1  5q21  Kidney 
OATP5A1  8q13.1  Heart, skeletal muscle, fetal brain# 
OATP6A1   5q21   Testis Spleen, brain, fetal brain, placenta# 
#
, identified only on the mRNA level 
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As shown in Table 2, the location of OATP encoding genes is varying among the 
particular family members. While genes which are situated at the short arm of 
chromosome 12 are encoding the members of the OATP1 family, the genetic 
information for OATP4C1 and 6A1 proteins is located on chromosome 5. The genes 
encoding OATP2A1, 2B1, 3A1, and 5A1 are allocated on chromosome 3, 11, 15, and 8, 
respectively.14 
While most of the OATP family members are expressed in a variety of different tissues, 
others of them are predominantly present in distinct organs.8,15 
3.1.3.1 OATP1A2 
OATP1A2 was the first human OATP identified and cloned from human liver, where it 
has been shown to be located in cholangiocytes.5,16 Beside its identification in human 
liver, this family member has been further detected in other tissues including brain, 
kidney, intestine, and ciliary body epithelium.5,16,17,18,19 Investigations on the localization 
of OATP1A2 in tissue samples of the human brain, using either immunofluorescence or 
immunohistochemical staining, showed high expression of this transporter in 
microvessels and endothelial capillaries but no staining in neurons or astrocytes.16,17 In 
human kidney, this OATP family member could be located in the apical domain of distal 
nephrons,16 while in the intestine it is expressed in the apical brush-border membrane of 
intestinal enterocytes.18 Regarding its location in enterocytes in more detail, OATP1A2 
is situated along the whole crypt–villus axis showing the highest protein expression on 
the villus tip.18 In human ocular tissues OATP1A2 was found to be present in the ciliary 
body epithelium were it is located in the basolateral membrane of the inner non-
pigmented epithelium.20 
3.1.3.2 OATP1B1 and 1B3 
Both members of the OATP1B subfamily, OATP1B1 and 1B3, were originally cloned 
from human liver, where they are found to be exclusively expressed under normal 
physiological conditions.21,22,23,24,25 Therefore, these OATP family members are 
designated “liver-specific”. Both transporters are located in the basolateral membrane of 
human hepatocytes. Nevertheless, they differ in their exact localization. While 
OATP1B1 is situated in the basolateral membrane of hepatocytes throughout the liver 
lobe, the expression of OATP1B3 is more restricted around the central vein.22,23,24 
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3.1.3.3 OATP1C1 
OATP1C1 was originally cloned from human brain and later it was also identified in 
human testes and the ciliary body of the human eye.20,26 In human brain, the expression 
of OATP1C1 was only investigated on mRNA level by Northern blot analysis using a 
multiple tissue expression array (Clontech Laboratories, Mountain View, CA), showing 
the presence of this transporter in a variety of brain regions, excepting in cerebellum 
and pons.26 In human testis, however, OATP1C1 localization was investigated by 
immunohistochemical staining, showing its expression in the nests of Leydig cells.26  
3.1.3.4 OATP2A1 
OATP2A1 was first cloned from human kidney in 1996.27 It was later identified in a 
variety of different tissues at mRNA level.28 Until now the protein of this transporter has 
been verified in human ocular tissue, gastrointestinal tract, endometrium, and 
brain.29,30,31,32 Studies focusing on the protein expression of OATP2A1 in human ocular 
tissues detected this OATP family member in the choroid/retinal pigment epithelium as 
well as in cornea, conjunctiva, iris, and the ciliary body.29 In the upper gastrointestinal 
tract OATP2A1 could be localized in the antrum as well as in the corpus and duodenal 
mucosa, showing highest protein expression in the antrum.30 Investigations on the 
protein localization in human endometrium revealed that OATP2A1 is situated in luminal 
and glandular epithelial and stromal cells. Interestingly, differences in protein expression 
in the endometrium were seen during the menstrual cycle, showing a higher OATP2A1 
expression during the proliferative and early secretory phase compared to the mid and 
late secretory phase.31 In human brain, OATP2A1 is localized in neurons, microglia, and 
astrocytes.32 
3.1.3.5 OATP2B1 
The coding sequence of OATP2B1 was first predicted in 1998 as a result of a cDNA 
sequencing project using size fractioned human brain cDNA libraries.33 Two years later 
it was first isolated from human brain.27 Thereafter, OATP2B1 mRNA was detected in 
numerous tissues including pancreas, liver, lung, colon, small intestine, ovary, testis, 
heart, placenta, kidney, and spleen. But highest expression levels were observed in 
human liver.27,34,35 Protein expression in human liver could be confined to the 
basolateral membrane of hepatocytes.34  
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Various data are available focusing on the expression of the OATP2B1 protein in 
different tissues, illustrating that this transporter is widely distributed in the human body. 
In the small intestine, OATP2B1 expression is restricted to the apical surface of 
enterocytes but is not expressed in goblet cells.36  
In human placenta, OATP2B1 was found to be located in the basal membrane of the 
syncytiotrophoblast.37 A closer examination of its exact localization in human placenta 
showed clear expression in membranes of the cytotrophoblast and, after differentiation, 
on the basal surface of the syncytiotrophoblast throughout first, second and third 
trimester placenta. Interestingly, a lower expression of OATP2B1 was seen in the 
proliferating cytotrophoblasts of the first trimester placenta when compared to the 
differentiated syncytiotrophoblast.38  
OATP2B1 was also identified in the mammary gland, where it is located to the 
contractile myoepithelial cells surrounding the ducts.39 Furthermore, this OATP family 
member could be detected in the human skeletal muscle,40 ocular tissue,20,29 and 
keratinocytes.41  
In human heart, it is located in the endothelium of capillaries, arteries, and veins.42 
Recent studies further identified OATP2B1 in human platelets and in megakaryocytes.43  
3.1.3.6 OATP3A1 
For OATP3A1, two variants have been identified and designated OATP3A1_v1 and 
OATP3A1_v2. OATP3A1_v1, first isolated from human kidney in 2000, represents the 
wild-type form,27 while OATP3A1_v2 is a splice variant and was first isolated from 
human brain (2007). The variant 2 is characterized by an additional splice donor site in 
exon 10, resulting in the lack of 18 amino acids at the COOH-terminal end.44  
OATP3A1_v1 is known to be ubiquitously expressed in humans and 
mammalians.20,27,40,41,44,45,46,47,48,49 Comparing the frequency of the two splice variants in 
the human body, OATP3A1_v1 exhibit a wider tissue distribution with higher mRNA 
levels, whereas the variant 2 seems to be predominantly present in human brain and 
testes.44 Additionally, differences have been also observed for the exact localization of 
OATP3A1 variants in these two organs. For example, in the choroid plexus of the 
human brain, OATP3A1_v1 is situated at the basolateral, while OATP3A1_v2 is rather 
expressed at the apical plasma membrane domain. Furthermore, in brain parenchyma, 
OATP3A1_v1 was only detected in neuroglial cells of the gray matter, while 
OATP3A1_v2 showed additional expression in the white matter.44 However, in testis, 
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the two OATP3A1 splice variants were determined in different developmental stages of 
germ cells with a more restricted expression pattern for OATP3A1_v1. Interestingly, 
OATP3A1_v2 was the only variant of this transporter present in sertoli cells.44 
3.1.3.7 OATP4A1 
OATP4A1 was first isolated from human kidney27 and brain50 by two independent 
groups in 2000 and 2001. Like OATP3A1, this OATP family member is known to be 
present in a variety of different tissues.27,50 On the mRNA level it was identified in 
mammary epithelial cells,49 placenta,48,50,51 human epidermal keratinocytes,41 mammary 
gland,40 fetal heart,52 adipose tissue,53 human jejunum,46 heart, lung, liver, skeletal 
muscle, kidney, and pancreas.27,50 However, information available on the expression of 
this transporter at the protein level is rare and, until now, verified only in the placenta, 
where it is located on the apical side of the villous membranes of the 
syncytiotrophoblasts,51,54 and the ciliary body epithelial of the human eye.20 
3.1.3.8 OATP4C1 
OATP4C1 was originally isolated from human kidney in 2004. Screening for OATP4C1 
mRNA expression in several human tissues revealed a restricted appearance in the 
adult as well as the fetal kidney. However, in fetal liver very low mRNA levels were 
seen.55 Immunohistochemical investigations on protein expression of this transporter in 
kidney have only been performed for the rat ortholog Oatp4c1, showing significant 
staining in the basolateral membrane of proximal tubule cells.55 
3.1.3.9 OATP5A1 
The open reading frame sequence of OATP5A1 has been identified by the Health 
Mammalian Gene Collection Program of the National Cancer Institute in 2001.56 
However, until now, data on the tissue distribution of OATP5A1 is very limited and only 
real-time RT-PCR analysis data in a panel of normal tissues have been published 
showing high mRNA expression in skeletal muscle, heart, and fetal brain. Lower 
expression was seen in thymus, stomach, prostate, and adult brain.57 
3.1.3.10 OATP6A1 
OATP6A1 has been first isolated from human testis.58 Faint mRNA expression levels of 
this OATP-family member were further seen in spleen, brain, fetal brain, and 
placenta.57,59 
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3.1.4 Physiological function 
Based on the characterization of OATP family members concerning their tissue 
distribution and functional properties it can be assumed that OATPs are uptake systems 
for endogenous and exogenous compounds, especially in organs with barrier functions, 
including liver, kidney, and the blood-brain barrier. Therefore, they are suggested to be 
important determinants in substrate absorption, distribution and excretion. However, 
further studies are needed to clarify their exact physiological function as until now, the 
best characterized family members include the OATP1 family (OATP1A2, 1B1, 1B3) 
and OATP2B1.6,7,15,60 Based on the expression of OATP1A2 at the apical membrane of 
cells in the distal nephron, this OATP family member is suggested to reabsorb 
compounds which are secreted or filtered in the proximale tubule.16 (Figure 2B) 
Additionally, its presence in the blood-brain barrier may enable the uptake of drugs into 
the brain.17 Contrary, OATP1B1, 1B3, and 2B1 are known to be present in the 
basolateral membrane of the liver. (Figure 2A) In this organ they facilitate the uptake of 
potentially substrates from the blood into hepatocytes, bringing them to the metabolizing 
system and enable their biotransformation into more water-soluble metabolites for the 
excretion into the bile.60  
A B
 
Figure 2 Characterized uptake systems in hepatocytes (A) and the proximal tubule (B). OATP, Organic 
anion transporting polypeptides; OCT, organic cation transporter; NTCP, Na+/taurocholate 
cotransporting polypeptide; OAT, organic anion transporter; SMCT, sodium-monocarboxylate 
transporter; URAT, urate transporter; NaDC, sodium dependent dicarboxylate transporter.60 
With respect to the localization of the two designated “liver-specific” OATPs, OATP1B1 
and 1B3, in human hepatocytes it has been shown that OATP1B1 is present throughout 
the whole liver lobe, while 1B3 is restricted to the area surrounding the central vein. 
Therefore, OATP1B3 is assumed to function as a backup transporter for OATP1B1.60 
Although these OATPs are known to be present in several other tissues, their function 
there is still unknown. Furthermore, not all of the known human OATP family members 
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have been characterized concerning their tissue distribution and substrate specificity. 
Therefore, information on their specific role is lacking and requires additional 
investigations. 
3.1.5 Substrates 
While some of the OATP family members (e.g. OATP1A2, 1B1, 1B3) demonstrate a 
broad and overlapping substrate preference, others of them (e.g. OATP1C1, 2A1, 4C1) 
show a rather narrow substrate specificity. However, the substrate specificity of two 
family members, namely OATP5A1 and 6A1, is still unknown.15 Although various 
publications summarize the substrate characteristics of several OATP family 
members,6,7,15,60 no systematic studies are available investigating the chemical and 
structural requirements for OATP substrates. However, the existing knowledge 
concludes that anionic amphipathic organic compounds of high molecular weight 
beyond 450 Da are candidates for OATP mediated transport.7 Especially molecules with 
steroidal structure components (e.g. bile salts, steroid hormones and their conjugates), 
but also linear (e.g. cholecystokinin-8, deltorphin II) and cyclic peptides (e.g. [D-Pen2,5]-
Enkephalin) which are normally bound to proteins (e.g. albumin) were characterized as 
OATP substrates.7 (Table 3) 
Furthermore, neutral compounds and even some cations (e.g. N-methylquinidine) have 
been described as OATP substrates.8 Typical endogenous substrates include bile 
acids, steroid and thyroid hormones as well as their conjugates and eicosanoids.6,7 The 
role of OATPs in the absorption, distribution and excretion of endogenous compounds 
aroused the interest in the investigation of their transport ability for xenobiotics. Thus, 
various drugs have been identified as OATP substrates so far, including HMG-CoA 
reductase inhibitors, antibiotics, ACE inhibitors, endothelin receptor antagonist, 
thrombin inhibitor, opioid receptor agonists, and angiotensin II antagonists.7,15 
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Table 3 Substrates of human OATPs.6,7,15 
OATP1A2 endogenous Bilirubin, cholate, dehydroepiandrosteron-3-sulfate, deltorphine 
II, [D-Pen2,5]-enkephalin, estradiol-17β-glucuronide, estrone-3-
sulfate, glycholate, prostaglandin E2, taurocholate, 
taurochenodeoxycholate, tauroursodeoxycholate, thyroxin, 
triiodothyronine, reverse triiodothyronine  
 exogenous ADP-ajmalinium, atrasentan, bamet-R2, bamet-UD2, BQ123, 
bromosulfophthalein, chlorambuciltaurocholate, ciprofloxacin, 
CRC220, enoxacin, erythromycin, fexofenadine, gatifloxacin, 
Gd-B20790, imatinib, levofloxacin, lomefloxacin, methotrexate, 
microcystin-LR, N-Methyl-quinidine, N-methylquinin, norfloxacin, 
ouabain, pitavastatin, rocuronium, rosuvastatin, saqinavir, TR-
14035, unoprostone 
   
OATP1B1 endogenous Bilirubin, bisglucuronosyl bilirubin, chenodeoxycholyl-(Nε-NBD)-
lysine, cholate, dehydroepiandrosteron-3-sulfate, [D-Pen2,5]-
enkephalin, [D-Ala2,D-Leu5]-enkephalin, estradiol-17β-
glucuronide, estrone-3-sulfate, glycholate, 
glycoursodeoxycholate, leukotriene C4, leukotriene E4, 
monoglucuronosyl bilirubin, prostaglandin E2, taurocholate, 
tauroursodeoxycholate, thromboxane B2, thyroxin, 
triiodothyronine 
 exogenous ACU154, arsenic (arsenite, arsenate), atorvastatin, atrasentan, 
bamet-R2, bamet-UD2, benzylpenicillin, bosentan, bosentan 
metabolite (Ro 48-5033), BQ123, bromosulfophthalein, 
capsofungin, cerivastatin, demethylphalloin, enalapril, ezetimib 
glucuronide, fexofenadine, fluvastatin, methotrexate, 
microcystein-LR, olmesartan, phalloidin, pitavastatin, 
pravastatin, repaglinide, rifampicin, rosuvastatin, SN-38, 
temocapril, TR-14035, troglitazone sulfate, valsartan 
   
OATP1B3 endogenous Bilirubin, chenodeoxycholyl-(Nε-NBD)-lysine, cholate, 
cholecystokinin-8, dehydroepiandrosteron-3-sulfate, deltorphin 
II, [D-Pen2,5]-enkephalin, estradiol-17β-glucuronide, estrone-3-
sulfate, glutathione, glycholate, glycoursodeoxycholate, 
leukotriene C4, monoglucuronosyl bilirubin, 
taurochenodeoxycholate, taurocholate, taurodeoxycholate, 
tauroursodeoxycholate, thyroxin, triiodothyronine 
 exogenous Amanitin, atrasentan, bosentan, bosentan metabolite (Ro 48-
5033), BQ123, bromosulfophthalein, demethylphalloin, digoxin, 
docetaxel, enalapril, erythromycin, fexofenadine, fluo-3, 
fluvastatin, imatinib, methotrexate, microcystin-LR, olmesartan, 
ouabain, paclitaxel, phalloidin, pitavastatin, pravastatin, 
rifampicin, rosuvastatin, SN-38, telmisartan, TR-14035, 
valsartan 
   
OATP1C1 endogenous Estradiol-17β-glucuronide, estrone-3-sulfate, thyroxin, 
triiodothyronine, reverse triiodothyronine 
 exogenous Bromosulfophthalein 
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Table 3 continued 
OATP2B1 endogenous Dehydroepiandrosteron-3-sulfate, estrone-3-sulfate, 
pregnenolone sulfate, prostaglandin E2, taurocholate 
 exogenous Atorvastatin, benzylpenicillin, bosentan, bromosulfophthalein, 
CP-671305, fexofenadine, fluvastatin, glibenclamide, M17055, 
pitavastatin, pravastatin, rosuvastatin, unoprostone 
   
OATP3A1_v1 endogenous Deltorphin, estrone-3-sulfate, prostaglandin E1, prostaglandin 
E2, prostaglandin F2α, thyroxin, vasopressin 
 exogenous Benzylpenicillin, BQ123 
   
OATP3A1_v2 endogenous Arachidonic acid, estrone-3-sulfate, prostaglandin E1, 
prostaglandin E2, thyroxin, vasopressin 
 exogenous Benzylpenicillin 
   
OATP4A1 endogenous cAMP, estradiol-17β-glucuronide, estrone-2-sulfate, 
prostaglandin E2, reverse triiodothyronine, taurocholate, 
thyroxin, triiodothyronine 
 exogenous Benzylpenicillin, digoxin, methotrexate, ouabain, unoprostone 
   
OATP4C1 endogenous Thyroxin, triiodothyronine 
 exogenous Digoxin, methotrexate, ouabain, sitagliptin 
   
OATP5A1 
 Not verified 
   
OATP6A1 
 Not verified 
     
BQ123, endothelin receptor antagonist; CRC220, thrombin inhibitor; TR-14035, integrin dual antagonist; 
ACU154, metabolite of PKI166 a tyrosin kinase inhibitor; M17055, diuretic candidate; CP-671305, 
phosphodiesterase 4 inhibitor 
 
A possible explanation for the multispecificity of some OATP family members is the 
existence of multiple binding sites, which allows the recognition of such a variation of 
structurally different compounds as substrates.6 For OATP1B1 a high- and a low-affinity 
binding site has been identified for estrone-3-sulfate transport, resulting in biphasic 
kinetics of this substrate.61 Different binding sites have been further demonstrated for 
OATP1B3, OATP2B1, and 4C1 in inhibition/ stimulation studies.9,62,63 Although 
progesterone is not mediated by OATP2B1, it shows a stimulatory effect on estrone-3-
sulfate transport increasing the Km value about four fold. Contrary, higher 
concentrations of progesterone decreased the affinity of estrone-3-sulfate again. These 
findings indicate the existence of a high and a low affinity binding site for progesterone, 
causing a stimulative or inhibitory effect on estrone-3-sulfate transport, respectively.63 
Similar observations have been described for OATP4C1, which mediated the uptake of 
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digoxin and triiodothyronine. But when coadministered these two substrates, no 
inhibition could be observed, supporting the hypothesis of different binding sites for 
these substrates.9 Furthermore, depending on the OATP1B3 mediated substrate, 
clotrimazol showed an inhibitory or stimulatory effect indicating an interaction of the 
substrates with different binding sites.62 
3.1.6 Molecular structure 
OATPs are transmembrane transporter proteins encoded by genes consisting of 643-
722 amino acids.7 Computer based hydropathy calculations predict a 12 
transmembrane general molecular structure (Figure 3) for mammalian OATPs/Oatps, 
but no experimental data are available to verify these predictions.6  
 
 
Figure 3 Model of human OATP1B1. Black dots indicate amino acids which are conserved in 77 out of 97 
mammalian OATPs/Oatps, while greys mark cysteine residues. In extracellular loops 2 and 5 
(E2, E5) three N-glycosilation sites are marked as Y.6 
Regarding the calculated model, the large extracellular loop 5 (E5) between the 
transmembrane domains IX and X with ten cysteine residues is one of the predicted 
structural characteristic of the OATP/Oatp family.7  
Further common features of the OATP molecular structures are several assumed N-
glycosylation sites in extracellular loops E2 and E5 and the “superfamily signature” 
overlapping the border between extracellular loop E3 and the transmembrane domain 
21 
VI. This signature is formed by the highly conserved consensus sequence D-X-RW-
(I,V)-GAWW-XG-(F,L)-L (X, any amino acid) including three tryptophane residues and 
which is used for the identification of OATP/Oatp family members in other species by 
database searching.8 
3.1.7 Transcriptional Regulation  
The exact regulation mechanism of OATP expression is unknown, but evidences for 
possible regulation pathways are given in some studies. Some OATPs have been 
identified as targets for the hepatocyte growth factor (HGF), which is a ligand of the 
tyrosine kinase receptor c-met and has been shown to be involved in the regulation of 
cytochrome P450 expression.64,65,66,67 The treatment of human hepatocytes with HGF 
resulted in a down-regulation of OATP1B1 and 2B1 expression in a dose-dependent 
manner.68  
Other studies suggest the involvement of the proinflammatory cytokines IL-1β and IL-6 
in the regulation of OATP expression as they cause decreasing expression of some 
OATPs.69,70  
The activation of proteinkinase C may be another possible regulation mechanism, 
because its activation resulted in the phosphorylation of OATP2B1 and subsequently in 
a reduction of transport activity which may be due to OATP2B1 internalization.71 
Nuclear receptors like LXR (liver X receptor), FXR (farnesoid receptor) and PXR 
(pregnane receptor) as well as other xenobiotic receptors including Ahr (aryl-
hydrocarbon receptor) and CAR (constitutive androstane receptor) are further 
hypothesized to be involved in the regulation of altered OATP expression.72,73,74,75,76,77  
In addition it has been reported that prolactin and growth hormone induced OATP1B3 
expression via stat5 (the signal transducers and activators of transcription 5), as 
mutated promoter regions encoding the stat5 binding site showed no hormonal 
induction of OATP1B3 expression.78 Regarding the binding sites for transcription 
factors, characterization of the promoter region is available for the OATP1A2, 1B1, and 
4C1 family members describing the existence of recognition sites for ubiquitous 
(activator protein AP1 and AP3, octamer binding site Oct-1, transcription initiation factor 
TFIID, CAAT element, nuclear factor NF-1) as well as liver-enriched transcription factors 
(hepatocyte nuclear factors HNF1, HNF3, HNF4, HNF5, CCAAT-enhancer binding 
protein CEBP-β).79,80,81 Regarding the liver-specific presence of OATP1B1, HNF1α is 
suggested to play an essential role in hepatocyte-specific expression.80 
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3.1.8 Transport mechanism 
Little is known about the exact transport mechanism of OATPs/Oatps. There are some 
studies dealing with potential driving forces of OATP/Oatp mediated transport, but no 
systematic investigations are available for all known OATP/Oatp members. While some 
examinations were performed for human OATPs, others especially focused on the 
family members in rats. But based on the amino acid homology (31%-82%)7 and 
common structural features of mammalian OATPs/Oatps, it can be suggested that they 
exhibit similar transport mechanisms. Available studies on the transport mode of the 
OATP/Oatp family examined on the one hand side the influence of extra- and 
intracellular conditions including pH-changes and ion-gradients on transport function. 
On the other side, they investigate the importance of structural features on the transport 
activity of OATPs/Oatps as they show conserved structural identities (see 3.1.6.). 
3.1.8.1 Influence of extra- and intracellular conditions on transport function 
Ion-gradients 
The OATP/Oatp superfamily has been identified as a Na+-independent transport system 
for bile acids in the liver. More detailed investigations on the transport mode of this 
family showed that the transport mediated by Oatps/OATPs is furthermore independent 
of K+ and Cl- gradients5,4,82,83,84 and the replacement of Na+ with other cations like K+, 
Li+, Rb+, choline or N-methyl-D-glucamine had only little effect on the transport.46 
ATP levels and membrane potential 
OATP mediated transport has been reported to be ATP-independent.85 Furthermore, 
membrane potential seems not to be a driving force for the transport activity of 
Oatp/OATP family members as depolarization did not effect OATP1B1/ 1B3 mediated 
estrone-3-sulfate transport.86  
pH-sensitivity 
There is evidence for a pH-sensitive OATP mediated transport. With the exception of 
OATP2A1, 5A1, and 6A1, for all other OATPs, studies are available investigating the 
effect of the pH in the extracellular medium on OATP-mediated substrate transport. 
Although Mahagita et al. (2007) reported no effect of pH changes on OATP1B1 or 1B3 
mediated estrone-3-sulfate uptake,86 a stimulating effect of a more acidic pH (pH 5.0-
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6.5) on the transport activity of OATPs expressed in Xenopus laevis oocytes was shown 
for OATP1A2, 1B1, 1B3, 2A1, 2B1, 3A1_v1, 3A1_v2, 4A1, and 4C1.87,88,89  
Interestingly, OATP1C1-mediated transport of substrates like taurocholate, estrone-3-
sulfate, prostaglandine E2, and thyroxin was not affected by changes of the extracellular 
pH, leading to the hypothesis that the transport mechanism of this family member differs 
from that of the other OATPs.87 Further experiments should clarify the effect of different 
pH values on the kinetic parameters of OATP1B1-, 1B3- and 1C1- mediated estrone-3-
sulfate and thyroxin transport. Again, with the exception of OATP1C1 transport which 
left unaffected, a decrease of Km values at acidic extracellular pH was revealed. 
However, the Vmax values were not significantly changed, suggesting that lowering the 
pH results in a higher affinity of the substrate to the respective transporter.87 To explain 
the observed different transport characteristics of OATP1C1, the amino acid sequence 
of OATP1C1 was compared with that of OATP1B1 and 1B3, which exhibited pH-
sensitivity, showing the replacement of a highly conserved histidine residue by a 
glutamine residue in the transmembrane domain III, which faces the extracellular 
space.87  
Remarkably, it has been shown that histidine residues are important for pH-sensitive 
transport mechanisms in other transporter families as well. This was shown for the 
peptide transporters PepT1 and PepT2,90,91 folate transporters,92 Na+/H+ exchanger93,94 
or the organic cation/H+ antiporter.95 As the pKa value for histidine in proteins is 6.9,96 
protonation of the imidazole ring and a positive charge is caused by shifting the 
extracellular pH to acidic conditions, and this could explain the importance of this amino 
acid for the pH-sensitivity of transporters. In case of OATP1C1, an exchange of the 
glutamine residue in position 130 by histidine led to a significant increase of the 
transport activity for the typical OATP1C1 substrate thyroxin at acidic pH (pH 6.5) 
compared to the transport activity at pH 8.0.87  
In accordance to these findings and supporting the hypothesis that the histidine residue 
in the transmembrane domain III is important for pH-dependent stimulation of 
Oatp/OATP mediated transport, the rat Oatp1a1 mutant His107Gln showed no 
increased substrate uptake at lower pH value.87 
Exchange with bicarbonate and proton gradient 
The finding of a pH related transport activity further proposed an association of OATP-
mediated transport either with an anion (HCO3- or OH-) exchange or an H+ cotransport. 
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A possible involvement of bicarbonate exchange in the transport mechanism was 
studied for the uptake of the typical substrate estrone-3-sulfate in OATP1B3 or 2B1 
transfected CHO cells. Cells were preloaded with HCO3- and intracellular pH was 
measured after the addition of the substrate to the extracellular medium, showing an 
higher intracellular acidification rate in the OATP-transfected cells compared to the 
control without HCO3- preload.87 This finding indicates an exchange of estron-3-sulfate 
and bicarbonate for these human transporters and is in accordance to the observations 
for rat Oatp mediated transport.83,97  
Beside the observed exchange of bicarbonate, an involvement of an H+-gradient in 
OATP/Oatp transport mechanism has been revealed for OATP2B1. For estrone-3-
sulfate uptake studies in OATP2B1 transfected cells an inwardly directed H+-gradient 
was generated by the adjustment of the intracellular pH to 7.4 and the extracellular pH 
to 6.0, resulting in an overshoot phenomenon of substrate accumulation. In absence of 
the H+-gradient or an additional treatment with the H+-ionophore carbonylcyanide-p-
trifluoromethoxyphenylhydrazone the lack of the overshoot phenomenon was observed, 
indicating that the uptake of estrone-3-sulfate via OATP2B1 is partially driven by a 
proton gradient.46,98 
Involvement of glutathione in OATP mediated transport 
Experiments for rat Oatp members indicate that glutathione efflux is coupled to Oatp 
mediated uptake of various substrates. At high intracellular glutathione concentrations, 
stimulation of taurocholate or digoxin uptake could be observed for rat Oatp1a1 and 1a4 
expressed in Xenopus laevis oocytes.99,100 Detailed investigations on the stoichiometry 
of the glutathione efflux/ taurocholate uptake for rat Oatp1a1 showed an 1:1 anion 
exchange.100  
However, reducing the physiological gradient between the intra- and the extracellular 
glutathione concentration by addition of glutathione to the extracellular medium showed 
only minimal stimulative effect on taurocholate and digoxin uptake via Oatp1a4. This 
indicates that uptake by Oatp1a4 is not driven by an outwardly directed glutathione 
transmembrane gradient, but the presence of high intracellular glutathione 
concentrations may favor the uptake.99 This asymmetric transport mechanism is also 
supported by an observed interaction of Oatp1a4 with the glutathione- conjugate S-(2,4-
dintriphenyl)-glutathione (DNP-SG). Although transport of DNP-SG is not mediated by 
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Oatp1a4, its intracellular presence stimulates the uptake of taurocholate, which is a 
known substrate for this transporter.99  
Whether human OATPs work as glutathione exchangers has only been investigated for 
a limited number of OATP family members and results are controversial. Briz et al 
(2006) showed that OATP1B3 expressed in Xenopus laevis oocytes transport bile acids 
with higher rates when glutathione or oxidized glutathione was added to the 
extracellular medium, while bicarbonate was not able to activate transport of taurocholic 
acid under these conditions.101 Interestingly, an inwardly directed glutathione gradient 
inhibited the efflux of cholic acid by OATP1B3, excluding the possibility of an exchange 
of cholic acid with glutathione as transport mechanism.101 Further investigations showed 
that glutathione itself is transported by OATP1B3 and kinetic analysis of bile acid 
transport in the presence of glutathione showed increasing Vmax but unchanged Km 
values. This suggests symport of anions and glutathione in the ratio of 1:2 by 
OATP1B3.101 Controversial results were presented in another study, showing neither 
cis- nor trans-stimulation of OAT1B3 mediated transport by glutathione or oxidized 
glutathione, excluding the suggestion that OATPs function as glutathione symporter or 
exchanger.86 OATP1B1 and 2B1 mediated transport is further described to be 
independent of glutathione.98,101 
Bidirectional transport 
Investigations on bidirectional transport ability of OATP1B3 revealed that OATP1B3 
expressed in Xenopus laevis oocytes is able to mediate efflux of intracellular loaded 
cholic acid.101 This OATP1B3 mediated efflux was further trans-stimulated by the 
addition of taurocholic acid to the extracellular medium.101 
3.1.8.2 Molecular structural requirements for OATP-mediated transport  
The extracellular loop 5 
The large extracellular loop 5 between the transmembrane domains IX and X with ten 
cysteine residues seem to be responsible for the expression of these transporters in cell 
membranes and therefore for their transport activity as this is reported for OATP2B1.102 
Hänggi et al (2006) generated nine cystein-to-alanin substitutions in the extracellular 
loop 5 and mutants were investigated concerning their cellular localization and transport 
activity for estrone-3-sulfate in transfected CHO-K1 cells.102 With exception of the wild-
type OATP2B1 and the mutant Cys493Ala, all other mutant proteins as well as the 
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truncated OATP2B1∆489-557 showed intracellular localization. Additionally, the mutants 
Cys493Ala and Cys557Ala achieved 60% and 30% of estrone-3-sulfate transport 
compared to the OATP2B1 wild type, respectively. All other OATP2B1 mutants showed 
a 85% decrease in estron-3-sulfate transport rate. These data demonstrate that the 
cysteine residues in extracellular loop 5 seem to be necessary for the expression of the 
transporter on the cell surface and therefore for its ability to transport estrone-3-
sulfate.102 
PDZ domain 
In addition, an oligomerization of OATPs/Oatps with a PDZ domain is suggested to be 
essential for proper subcellular localization and therefore its function.103  
PDZ domains consist of approximately 90 amino acids and are one of the most 
represented protein domains in sequenced genomes. The acronym “PDZ” is composed 
of the first three identified proteins containing PDZ domains.104 (Table 4) 
Table 4 Composition of the acronym “PDZ“.104 
PSD-95/SAP90  Postsysnaptic protein 
Discs-large  Drosophila septate junction protein 
ZO-1  Tight junction protein 
 
PDZ domains mediate protein-protein interactions by binding to the C-terminus of the 
target protein. Therefore they assemble protein complexes, which have been reported 
to organize signaling pathways, cell polarity and subcellular location.104  
Several OATPs/Oatps have been identified to exhibit a PDZ consensus binding site at 
their C-terminal, including the human OATP1A2 and 2B1 and the rat Oatp1a1, 1a4, 
1b2, and 2b1.103 Sequence alignment analysis of the C-terminus sequences of the 
human OATPs 1A2, 1B1, 1B3, 1C1, 2B1, 3A1, and 4A1 revealed consistence with the 
binding motif of Class I PDZ domains, characterized by a X(S/T)XΦ sequence (X, any 
amino acid possible; Φ, hydrophobic amino acid), for OATP1A2, 3A1, and 4A1.103,104,105 
Additional yeast two-hybrid analysis verified a positive interaction of human OATP1A2, 
1C1, and 3A1 with PDZ proteins.105 Detailed investigations on the involvement of 
protein interaction with PDZ domains in the localization of OATPs/Oatps showed that in 
contrast to a basolateral membrane localization of Oatp1a1 in wild type mice shifted to a 
predominantly intracellular distribution when PDZ was knocked-out.103 Whether PDZ-
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interaction is necessary for transmembrane localization of human OATPs has to be 
evaluated. 
The transmembrane domains 8 and 9 
The importance of the molecular structure on OATP transport has been further 
investigated in another study using HEK293 cell lines transfected with chimeric 
OATP1B1 transporters by Miyagawa et al (2009).106 Chimeric OATP1B1 mutants were 
generated by the substitution of different OATP1B1 transmembrane domains with those 
of OATP1B3. After transfection, kinetic analyses were performed for the typical 
OATP1B1 substrate estrone-3-sulfate and for estradiol-17β-D-glucuronide, a substrate 
accepted by both- OATP1B1 and 1B3- transporters. While transport kinetics of 
estradiol-17β-D-glucuronide were not changed by the substitution of the 
transmembrane domain 9 of OATP1B1 with that of OATP1B3, a significant increase 
(7.4-fold) of the Km values for estrone-3-sulfate was observed for this OATP1B1 chimer. 
Contrary, the exchange of the OATP1B1 transmembrane domain 8 with that of 
OATP1B3 caused an increased Km value for estrone-3-sulfate (18-fold) but showed no 
transport activity for estradiol-17β-D-glucuronide. These results indicate an important 
role of the transmembrane domain 8 and 9 for OATP1B1 mediated transport activity.106 
The transmembrane domain 10 
In addition, such chimeric proteins between OATP1B1 and 1B3 were further generated 
and transfected into HEK293 cells in another study, investigating cholecystokinin uptake 
by different chimeric OATP1B1-1B3 proteins.107 This study showed that cholecystokinin 
uptake was dramatically reduced when the transmembrane domain 10 of OATP1B3 
was replaced by that from OATP1B1, indicating an important role of the transmembrane 
domain 10 in the transport of cholecystokinin. More detailed investigations identified 
three key residues in position Y537, S545, and T550 in this transmembrane domain of 
OATP1B3. Replacing these amino acids in OATP1B3 with the corresponding ones of 
OATP1B1 resulted in similar reduced cholecystokinin uptake as observed after the 
replacement of the whole transmembrane domain 10. Therefore, it is suggested that the 
three amino acids Y537, S545 and T550 in OATP1B3 are important for the uptake of 
cholecystokinin via this transporter.107 
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Rocker-switch type of transport mechanism 
Furthermore, structural models of OATP1B3 and 2B1 predict the presence of a central 
positively charged pore, which seems to be functionally important as the positive 
electrostatic potential and the size of this pore is consistent with the shape of typical 
OATP/Oatp substrates. However, this model has to be experimentally verfied.13  
Moreover, investigations of known polymorphisms in the OATP1B and 2B family 
correspond with this proposed rocker-switch type of transport mechanism. Reported 
polymorphisms in OATP1B1108 and 2B188 are indeed associated with changes in Km 
and Vmax values for e.g. estrone-3-sulfate transport. This supports the suitability of the 
predicted model, particularly as related amino acid residues face the suggested central 
pore. This may therefore be important for substrate recognition and binding.13  
3.2 OATPs and malignancies 
Although it has been demonstrated that drugs used in the treatment of cancer are 
substrates of OATP family members, the current knowledge on the distribution and 
functions of individual OATPs in malignant tissues is limited.  
OATP1A2 has been shown to mediate the uptake of methotrexate, while the 1B3 family 
member was identified as high affinity paclitaxel transporter.109,110 In addition, OATPs 
may be important in cancer diagnosis and prognosis as OATP1B1 and 1B3 are 
suggested to be histological markers in the diagnosis of hepatocellular carcinomas and 
additionally OATP1B3 has further been shown to be a prognostic factor in invasive 
ductal carcinomas of the breast.111, 112  
3.2.1 OATPs in breast cancer 
Worldwide 14% of female cancer deaths are attributed to breast cancer and every year 
up to 5% increasing rates in breast cancer incidences are predicted.113 Estrogens are 
known to be important determinants in the progression of estrogen-dependent breast 
cancers. The sources of active estrogens are circulating androstendione and estrone-3-
sulfate which are converted to active estrogens in tumor cells either in the aromatase or 
sulfatase pathway (Figure 4).114 As sulfatases showed a higher activity in breast cancer 
patients than aromatase, they are likely to be the main estrogen producing enzymes.115  
In contrast to the estrogen-sulfate hydrolyzing sulfatases, which produce biological 
active 17ß-estradiol, enzymes belonging to the sulfotransferase family (SULT) are able 
to convert active estrogens, particularly 17ß-estradiol with help of the ß-
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hydroxysteroide-dehydrogenase, back into the inactive sulfoderivate estrone-sulfate. 
Both, sulfatases and SULTs have been reported to be highly expressed in breast 
tissue.116,117 
 
Figure 4 Production of active estrogens in human breast cancer cells. 17ß-HSD-1, 17ß-hydroxysteroid- 
dehydrogenase type 1; SULT, sulfotransferases. Modified from Pasqualini.117 
While estrogen converting pathways are well studied, the uptake mechanisms of the 
estrogen precursors into breast tumors are still not well characterized. Estrone-3-sulfate 
is the estrogen present at highest concentration in human serum and is a substrate for 
many OATPs.118 Therefore, it is hypothesized that OATPs play an important role in the 
transport of this conjugated estrogen into tumor cells and, thereby, influence estrogen-
dependent proliferation.  
Until now, data on the presence and localization of OATP family members in breast 
cancer tissue is limited. However, some of them have been studied in various breast 
cancer cell lines showing mRNA expression of several OATPs. 
OATP1A2 mRNA was reported to be present in T-47D, MCF-7, and ZR-75-1 cells, but 
absent in MDA-MB-231 and MDA-MB-468 cells.40,119 However, OATP1B1, 1B3, and 
1C1 mRNA was not present, neither in T-47D nor in MCF-7 cells, when determined with 
conventional PCR,120,121 but OATP1C1 was detectable in HS578T cells.119 Additionally, 
the liver specific OATP1B3 was shown to be present in MDA-MB-231 and HS578T 
cells.119 OATP2A1 mRNA could be detected in BT-549, HS578T, and MCF-7 cells,119 
while expression of OATP2B1 mRNA was undetectable in T-47D, MCF-7 or MDA-MB-
453 cell lines.120,121 mRNA of OATP3A1 and 4A1 has been detected in T-47D, MCF-7, 
and MDA-MB-453 breast cancer cell lines by conventional and real-time PCR.40,122,123  
OATP4C1 mRNA was found in MCF-7, BT-549, and MDA-MB-231 cells.119  
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However, only the expression of OATP2B1 was confirmed at the protein level so far and 
immunofluorescence staining experiments showed localization in epithelial cells in 
invasive ductal carcinoma.40  
For human breast cancer tissue, knowledge on OATP mRNA expression and OATP 
protein localization is even more limited. Both, OATP1A2 and 2B1 mRNA have been 
identified to be expressed in tumorous breast tissues.72.124 A study investigating 102 
specimens of invasive ductal carcinomas of the breast showed protein expression of 
OATP1B3. As its expression levels were associated with tumor size, OATP1B3 was 
regarded as a prognostic factor in breast cancer.112 
3.2.2 OATPs in liver malignancies 
The different tumor types occurring in the human liver are categorized by their place of 
origin. While the hepatocellular carcinoma arouses from hepatocytes, 
cholangiocarcinomas derive from cells in the bile duct (bile ductular cells, 
cholangiocytes). In addition to these malignancies which are derived from cells of the 
liver itself, metastatic tumors deriving from malignancies of other organs often occur in 
the liver.125  
Under physiologic conditions, some OATPs are important influx transporters in the liver, 
mediating the uptake of compounds into hepatocytes. Today, our information on 
differences in the OATP expression pattern in hepatic malignancies is limited, as 
studies generally focus on the two liver-specific OATP1B1 and 1B3.  
OATP1B1 as well as OATP1B3 could be detected in hepatocellular carcinomas either 
on mRNA and protein level.126,127 More detailed investigations observed a decreased 
expression of OATP1B3 in hepatocellular carcinoma (HCC) specimens compared to the 
non-malignant tissue samples, but data on OATP1B1 expression are controversial. 
While some studies observed a reduced mRNA and protein expression of OATP1B1 in 
HCC tumor samples,126,127,128 others revealed no significant decrease of this transporter 
in tumorous specimens, neither on the mRNA nor on the protein level.129 Our 
knowledge of OATP distribution in cholangiocarcinomas and metastases is limited to 
the information that OATP1B1 and 1B3 could not be detected by immunofluorescence 
staining in these malignancies.126 
31 
3.2.3 OATPs in tumors of other organs 
OATPs have further been detected in other cancer types originated from lung, blood 
cells, brain, pancreas and the gastrointestinal tract.130,131,132,133,134,135,136 In colon 
cancers OATP1A2, 1B1, 1B3, and 4A1 have been identified so far.130,131,132 OATP1B3 
was additionally characterized in gastric and pancreatic cancer.131 The ubiquitous 
distributed OATP3A1 was also present in cell lines deriving from blood cell 
malignancies (promyelocytic leukemia, chronic myelogenous leukemia, lymphoblastic 
leukemia, Burkitt’s lymphoma) and various solid tumors, including cervical cancer, 
colorectal adenocarcinoma, lung carcinoma, and melanoma.133 In human brain tumors, 
OATP1A2 and 2B1 showed localization at the blood-tumor barrier.134 However, in lung 
cancers, eight OATP family members have been identified so far, including OATP1A2, 
1B3, 1C1, 2A1, 2B1, 3A1, 4A1, and the less characterized OATP6A1.135,136 The latter 
has further been detected in bladder and esophageal tumors.136 
Although OATPs have been identified in these different types of tumors and they are 
reported to mediate the transport of some anticancer agents, no systematic studies are 
available. Taken together, it can be hypothesized that this transporter family may 
contribute to uptake of anticancer agents into cancer cells and subsequently to efficacy 
of cancer therapy. However, further studies are required to get more insight in the role 
of OATP family members in malignancies. 
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5 AIMS OF THE THESIS 
Organic anion transporting polypeptides (OATPs) have been reported to mediate the 
uptake of endogenous and exogenous compounds, including bile acids steroid 
hormones and their conjugates as well as antibiotics, statins, and antihypertensive 
drugs. Until now eleven family members have been identified in humans, exhibiting 
distribution in a variety of different tissues. The localization of OATPs in organs like 
intestine, liver, kidney, and brain indicate a key role in absorption, disposition and 
elimination of exogenous compounds. Indeed, studies in OATP-expressing X. laevis 
oocytes and cancer cell lines show that OATPs mediate the influx of xenobiotics, 
including anticancer agents into cells, suggesting an important role of these transporters 
also for the uptake of anticancer drugs into tumor cells. Nevertheless, the knowledge on 
OATP expression and function in malignancies is limited and their possible role in 
chemoresistance of tumor cells is still unknown. To account for these problems, the aim 
of this thesis was to investigate the presence of this transporter family in selected 
cancer types. A potential difference in mRNA expression rates between malignant and 
non-malignant tissues should be investigated. First, real-time PCR analyses should 
detect mRNA expression of all known human OATPs in three common used breast 
cancer cell lines and one non-malignant breast cell line. To verify whether these cell 
lines are useful in vitro models for human tissues, data from OATP mRNA expression 
analyses in cell lines were compared to OATP mRNA expression pattern in breast 
cancer tissue samples from 13 patients. To examine possible variations in the mRNA 
expression levels between tumorous and normal tissue, adjacent non-malignant 
specimens from the same patient were included into real-time PCR analyses.  
Estrogen-dependent tumor progression is a severe problem in many patients with 
breast cancer. Particularly after menopause, adrenal-derived inactive estrone-3-sulfate 
is effectively hydrolyzed by sulfatases in breast cancer cells to provide active 17ß-
estradiol leading to the proliferation of hormone-dependent tumor cells. However, 
counteracting sulfotransferases (SULTs) are able to convert estrogens back into its 
inactive precursor estrone-3-sulfate. To get a better insight in the expression levels of 
sulfatases and SULTs in breast cancer cells, mRNA expression of these enzymes were 
further investigated in malignant and non-malignant breast cancer tissue samples. 
Another topic of this thesis is the investigation on the anticancer agent paclitaxel, used 
in the treatment of metastatic breast cancer, regarding its substrate activity for 
48 
OATP1B1 and 1B3. However, whether all other OATP family members, identified in 
humans, show substrate specificity for paclitaxel, has not been studied yet. The next 
aim was to characterize all eleven human OATPs concerning their ability to transport 
paclitaxel in the Xenopus laevis oocytes expression model. Therefore, full length cRNAs 
of all eleven OATP family members were generated, injected into Xenopus laevis 
oocytes, and the uptake of radiolabeled paclitaxel was measured. Furthermore, kinetic 
analysis of paclitaxel transport mediated by the OATPs identified as paclitaxel 
transporters was performed. 
Beside paclitaxel, other anticancer agents including methotrexate have been identified 
as OATP substrates so far. As methotrexate is commonly used in the treatment of 
osteosarcomas, another aim of this study was to elucidate the expression pattern of this 
transporter family in specimens derived from 21 patients suffering from osteosarcomas 
using real-time PCR. In addition, this project should examine mRNA levels of all OATPs 
in common used osteosarcoma cell lines and non-malignant bone cells.  
In addition to the uptake of xenobiotics into target organs, metabolism and elimination 
are other important determinants for an effective anticancer chemotherapy with minor 
side- or toxic effects. Most part of metabolism reactions take place in the liver, where 
two members of the OATP family (1B1 and 1B3) are situated in the basolateral 
membrane of hepatocytes, facilitating the uptake of drugs and bringing them to the 
metabolizing system. Although the importance of some OATPs in human liver has been 
well investigated, the overall role of all OATPs in liver malignancies is still unclear. 
Therefore, another aim of this thesis was to investigate the expression of all known 
human OATP family members in tumorous liver tissues from 22 patients by real-time 
PCR. Again, the corresponding non-tumorous tissue samples from the same patients 
were also examined to detect a possible change in mRNA expression rates comparing 
tumor and normal specimens. To cover the three most frequent malignant tumors in 
human liver, the samples derived from patients suffering from hepatocellular-, 
cholangiocarcinomas or metastases from tumors of other organs were investigated for 
expression all OATPs and studied differences in the OATP mRNA expression pattern 
between these liver tumors.  
The results from these studies should allow a better understanding in the role of OATPs 
in frequent human cancer, e.g. breast and liver cancer. This would contribute to better 
understand mechanisms leading to the sensitivity of tumors against chemotherapeutic 
drugs. 
49 
6 RESULTS 
6.1 Original papers and manuscripts 
Wlcek K, Svoboda M, Thalhammer T, Sellner F, Krupitza G, Jaeger W. Altered 
expression of organic anion transporter polypeptide (OATP) genes in human breast 
carcinoma. Cancer Biol Ther. 2008; 7:1450-5. 
 
Liedauer R, Svoboda M, Wlcek K, Arrich F, Jäger W, Toma C, Thalhammer T. Different 
expression patterns of organic anion transporting polypeptides in osteosarcomas, bone 
metastases and aneurysmal bone cysts. Oncol Rep. 2009; 22:1485-92. 
I carried out RNA isolation of selected bone tumor specimens. 
 
Miksits M, Wlcek K, Svoboda M, Thalhammer T, Ellinger I, Stefanzl G, Falany CN, 
Szekeres T, Jaeger W. Expression of sulfotransferases and sulfatases in human breast 
cancer: impact on resveratrol metabolism. Cancer Lett. 2010; 289:237-45. 
I carried out RNA isolation, reverse transcription, and real-time PCR analysis 
 
Wlcek K, Svoboda M, Riha J, Stefanzl G, Olszewski U, Dvorak Z, Sellner F, Jäger W, 
Thalhammer T. Analysis of organic anion transporting polypeptide (OATP) mRNA and 
protein reveals differences in primary and metastatic liver cancer. Cancer Biol Ther. 
Submitted April 2010. 
 
Svoboda M, Wlcek K, Taferner B, Hering S, Stieger B, Tong D, Zeillinger R, 
Thalhammer T, Jäger W. Paclitaxel transport by organic anion transporting polypeptides 
(OATPs) in the ovarian cancer cell lines OVCAR-3 and SK-OV-3. Cancer Lett. 
Submitted May 2010. 
 I carried out Plasmid/cRNA generation and transport studies 
50 
51 
6.1.1 Wlcek K, Svoboda M, Thalhammer T, Sellner F, Krupitza G, Jaeger W. 
Altered expression of organic anion transporter polypeptide (OATP) genes 
in human breast carcinoma. Cancer Biol Ther. 2008; 7:1450-5. 
 
 
 
 
 
 
 
 
ALTERED EXPRESSION OF ORGANIC ANION TRANSPORTER POLYPEPTIDE 
(OATP) GENES IN HUMAN BREAST CARCINOMA 
 
Wlcek K, Svoboda M, Thalhammer T, Sellner F, Krupitza G, Jaeger W 
 
Cancer Biol Ther. 7:1450-5, 2008 
52 
53 
54 
55 
56 
57 
58 
59 
6.1.2 Liedauer R, Svoboda M, Wlcek K, Arrich F, Jäger W, Toma C, Thalhammer 
T. Different expression patterns of organic anion transporting polypeptides 
in osteosarcomas, bone metastases and aneurysmal bone cysts. Oncol 
Rep. 2009; 22:1485-92. 
 
 
 
 
 
 
 
DIFFERENT EXPRESSION PATTERNS OF ORGANIC ANION TRANSPORTING 
POLYPEPTIDES IN OSTEOSARCOMAS, BONE METASTASES AND ANEURYSMAL 
BONE CYSTS 
 
Liedauer R, Svoboda M, Wlcek K, Arrich F, Jäger W, Toma C, Thalhammer T 
 
Oncol Rep. 22:1485-92, 2009 
60 
61 
62 
63 
64 
65 
66 
67 
68 
69 
6.1.3 Miksits M, Wlcek K, Svoboda M, Thalhammer T, Ellinger I, Stefanzl G, 
Falany CN, Szekeres T, Jaeger W. Expression of sulfotransferases and 
sulfatases in human breast cancer: impact on resveratrol metabolism. 
Cancer Lett. 2010; 289:237-45. 
 
 
 
 
 
 
 
EXPRESSION OF SULFOTRANSFERASES AND SULFATASES IN HUMAN 
BREAST CANCER: IMPACT ON RESVERATROL METABOLISM 
 
Miksits M, Wlcek K, Svoboda M, Thalhammer T, Ellinger I, Stefanzl G, Falany CN, 
Szekeres T, Jaeger W 
 
Cancer Lett. 289:237-45, 2010 
70 
71 
72 
73 
74 
75 
76 
77 
78 
79 
80 
81 
6.1.4 Wlcek K, Svoboda M, Riha J, Stefanzl G, Olszewski U, Dvorak Z, Sellner F, 
Jäger W, Thalhammer T. Analysis of organic anion transporting 
polypeptide (OATP) mRNA and protein reveals differences in primary and 
metastatic liver cancer. Cancer Biol Ther. Submitted April 2010. 
 
 
 
 
 
 
 
ANALYSIS OF ORGANIC ANION TRANSPORTING POLYPEPTIDE (OATP) mRNA 
AND PROTEIN REVEALS DIFFERENCES IN PRIMARY AND METASTATIC LIVER 
CANCER 
 
Wlcek K, Svoboda M, Riha J, Stefanzl G, Olszewski U, Dvorak Z, Sellner F, Jäger W, 
Thalhammer T 
 
Cancer Biol Ther. Submitted April 2010 
82 
83 
TITLE PAGE 
 
Analysis of organic anion transporting polypeptide (OATP) mRNA and protein 
reveals differences in primary and metastatic liver cancer 
 
Katrin Wlcek1, Martin Svoboda2, Juliane Riha1, Gabriele Stefanzl1, Ulrike Olszewski3, 
Zdenek Dvorak4, Franz Sellner 5, Walter Jäger1, Theresia Thalhammer2 
 
1Department of Clinical Pharmacy and Diagnostic, University of Vienna, Austria 
2Institute of Pathophysiology, Medical University of Vienna, Austria 
3Ludwig Boltzmann Cluster of Translational Oncology, Vienna, Austria 
4Department of Cell Biology and Genetics, Palacky University Olomouc, Czech 
Republic 
5Department of Surgery, Kaiser-Franz-Josef-Spital, Vienna, Austria 
 
CORRESPONDING AUTHOR 
Ao. Univ. Prof. Dr. Theresia Thalhammer 
Institute of Pathophysiology 
Medical University of Vienna, AKH 
Währingergürtel 18-20, 3Q 
A-1090 Vienna, Austria 
Tel.: +43-1-40400-5128 
Fax: +43-1-40400-5130 
theresia.thalhammer@meduniwien.ac.at 
 
KEY WORDS 
OATP, liver, hepatocellular carcinoma, cholangiocarcinomas, colon metastases, 
cholangiocytes, hepatocytes, transporter, HepG2, PCR, immunofluorescence 
 
ACKNOWLEDGEMENTS 
This work was supported by the OVCAD STREProject [FA751C0203], the 
Jubiläumsfonds der Österreichischen Nationalbank [12600] and the FWF [P21083-B11]. 
 
 
84 
ABBREVIATIONS 
OATP, organic anion transporting polypeptides; HCC, hepatocellular carcinoma; CCC, 
cholangiocarcinoma; MLT, metastatic liver tumors 
 
CONFLICT OF INTEREST 
All authors have disclosed no financial relationships and conflict of interest. 
85 
ABSTRACT 
Transmembrane transporters for endobiotics and drugs from the organic anion 
transporting polypeptide (OATP) family are expressed in the liver and may be altered in 
cancer. Thus, we investigated mRNA expression of all eleven OATPs in paired 
cancerous and adjacent non-cancerous specimens (n=22) from hepatocellular (HCC), 
cholangiocellular carcinomas (CCC) and liver metastases (MLT). TaqMan® real-time 
RT-PCR analysis revealed that all OATPs except OATP1C1 and 6A1 are expressed in 
the majority of tissues samples. With the exception of OATP1A2, they are also 
expressed in primary hepatocytes and HepG2 cells. In comparing cancerous and non-
cancerous specimens, we found that mRNA expression levels were reduced for 
OATP1B1, 1B3, 1A2 and 2B1 and increased for OATP2A1, 3A1 and 5A1 in cancer 
samples. Differences were also seen between different tumor types. While 
downregulation of OATP1A2 and 1B3 mRNA expression was most pronounced in CCC, 
marked up-regulation of OATP4A1 and 5A1 mRNA was observed in MLT. 
Immunofluorescence studies for OATP2A1, 5A1 and 4A1 revealed immunoreactive 
plasma membrane staining in cancer cells. Staining of cytokeratin-19 positive cells in 
proliferating bile ducts was observed for OATP2A1 and 4A1. Further studies in HepG2 
cells revealed reduced mRNA levels of all OATPs except OATP4A1 and 4C1 when 
compared to human hepatocytes. Treatment of HepG2 cells with Aza-dC increased 
OATP2A1 and 5A1 mRNA expression to the level in hepatocytes, indicating that 
hypermethylation inhibits their expression. Distinct regulation of OATP expression in 
primary and metastatic hepatic tumors may alter uptake of drugs, hormones and 
prostaglandins, thereby influencing the efficacy of a given therapy. 
 
Running title: Altered OATP expression in liver cancer 
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INTRODUCTION 
Eleven members of the organic anion transporter family (OATP-family) have been 
identified in humans so far. They represent a group of sodium-independent 
transmembrane transporters for a broad spectrum of substrates, including hormones 
and their conjugates, prostaglandins, xenobiotics, and therapeutic drugs.1 Although the 
majority of human OATPs show wide tissue distribution, some members exhibit unique 
expression in distinct organs. The best studied of these are the “liver–specific” members 
OATP1B12,3 and 1B3.4 These OATPs are located in the basolateral membrane of 
hepatocytes where they mediate the uptake of endogenous substrates and drugs into 
the cell and play a critical role in the first step of the elimination process through the 
liver.5,6,7 In addition to OATP1B1 and 1B3, expression of the OATPs OATP1A2,8 2A1,9 
2B1, 3A1 and 4A110 was first investigated by Northern blotting and conventional PCR 
analysis, and in more recent studies, by real-time RT-PCR in normal liver.11,12 While 
robust expression of OATP1A2 and low levels of OATP3A1 and 4A1 mRNA were 
consistently reported, OATP2A1 was detected only by Northern blotting9 but not by 
conventional PCR analysis.10 
Investigations of OATP protein levels in liver are only available for a limited number of 
OATPs. Immunohistochemical studies showed that OATP1B1, 1B3 and OATP2B1 are 
located in hepatocytes,2,3,4,13 and OATP1A2 was detected in bile duct cells 
(cholangiocytes).14 
It is known that expression of some OATPs such as OATP1B3 is altered by malignant 
transformation of cells. In addition, confined expression to specific organs as seen in 
normal tissue can be lost.1 In a recent study from our lab, we show that OATP2B1, 3A1 
and 4A1 are differently expressed in breast cancer as compared to non-malignant 
tissue.15 Similarly, differences in OATP mRNA expression are also seen for primary and 
metastatic bone tumors,16 and a number of OATPs such as OATP1A2, 1C1, 2B1 and 
4A1 are expressed in human gliomas.17  
For liver cancers, studies have mainly focused on the two liver-specific OATP family 
members, OATP1B1 and 1B3.18,19 These transporters are down-regulated in the 
hepatoma cell line HepG220,11 and in liver cancer (hepatocellular carcinoma).19 
However, expression of other OATPs such as the prostaglandin transporter OATP2A1, 
the ubiquitously expressed OATP4A1, and the less characterized OATP5A1 has not 
been investigated in liver tumors as of yet.1 
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As OATPs regulate the uptake of metabolites, drugs, and xenobiotics, expression of 
OATPs in malignant liver disease may influence tumor progression as well as the 
response to chemotherapeutic interventions. Therefore, we investigated the presence of 
all eleven OATP family members in primary and metastatic liver tumors using paired 
cancerous and non-cancerous samples from 22 patients with the primary liver cancers 
hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCC) and metastases of 
solid tumors (MLT), the most frequent tumors in the liver.21 Additionally, we assessed 
OATP mRNA expression in HepG2 cells treated with the demethylating agent 5-aza-2´-
deoxycytidine (Aza-dC) and compared it to that of hepatocytes derived from nine human 
donors.  
Differential expression of individual OATPs in cancerous and normal liver might alter the 
uptake of signaling molecules including hormones, prostaglandins and anticancer drugs 
into hepatic cells, thus affecting the proliferation of tumor cells. 
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RESULTS 
OATP mRNA expression in human malignant and non-malignant liver samples. 
To study possible changes in the expression pattern of all human OATPs in hepatic 
malignancies, paired cancerous (HCC (n=7), CCC (n= 5) and MLT (n=10)) and adjacent 
non-cancerous samples were analyzed for mRNA expression of all known human 
OATPs using real-time RT-PCR.  
The OATP mRNA expression profile is depicted as a heat map in Figure 1, showing a 
cluster of non-cancerous (“normal”) and of cancerous samples with distinct expression 
of OATPs. Exceptions were seen for HCC samples #1 and #17 and sample #2 from the 
non-cancerous part of an MLT, which fit into the normal and cancer clusters, 
respectively.  
Decreased mRNA expression in most cancerous samples was observed for the liver-
specific transporters OATP1B1 and 1B3, and other OATPs, OATP2B1, 1A2 and 4C1. 
However, expression of OATP2A1, 3A1 and 4A1 and the less characterized OATP5A1 
was increased in most of the malignant samples as compared to the non-cancerous 
specimens. OATP1C1 and OATP6A1 mRNA levels were below the detection limit in all 
but three samples, which showed only marginal levels of these transporters. 
Further analysis revealed relative quantitative differences in OATP levels between the 
HCC, CCC and MLT groups (Figure 2). Remarkably, OATP1B1, showed a 44- and 36-
fold decrease in CCC and MLT, respectively. Pronounced reduction of 1A2 and 1B3 
was also observed in the CCC group (113- and 75-fold, respectively). Decreases in 
OATP1B1 mRNA levels in HCC and OATP1B3 in HCC and MLT samples were 
moderate, up to 4-fold (p<0.05). Reduced expression was also seen for OATP2B1 in 
the CCC and MLT groups (4- to 7-fold).  
In contrast, an up to 34-fold increase was seen for OATP2A1, 3A1 and 5A1 mRNA 
expression in HCC, CCC and MLT samples. Interestingly, a 20-fold upregulation was 
observed for OATP4A1 in the MLT group, while levels in HCC and CCC did not differ 
compared to the nonmalignant controls. This may be related to an upregulation in 
OATP4A1 expression in colon cancer as suggested from previous array data22 and in 
our control samples (6-fold upregulation, n=24, data not shown). Expression of 
OATP4C1 mRNA was highly variable but similar to that in the non-cancerous samples. 
Analysis of cellular localization of OATP2A1, 4A1 and 5A1 by 
immunofluorescence. Localization of OATP2A1, 4A1 and 5A1, which have not been 
previously studied at the protein level in hepatic tumors, were analyzed by 
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immunofluorescence staining for their cellular localization on cryosections of tumors. In 
accordance with the real-time RT-PCR results, immunofluorescent staining of OATP2A1 
was more intense in the cancerous samples than in the non-cancerous controls. 
However, OAT2A1 staining was rather diffuse in the cytoplasm of liver parenchymal 
cells, and mostly membranous staining was visible in the cancer section, suggesting 
activation of the transporter in these tumors (Figure 3A). 
Only background fluorescence was observed in hepatocytes in the non-cancerous HCC 
and MLT samples with anti-OATP5A1 and 4A1 antibodies, respectively (Figure 3A). In 
the cancerous sections, OATP5A1 and 4A1 staining is clearly membrane associated. 
To investigate whether OATP2A1, 4A1 and 5A1 may also be expressed in cells deriving 
from proliferating bile ducts, we performed double staining with cytokeratin 19 (CK-19) 
as a marker for biliary/progenitor cells.23 Remarkably, while OATP2A1 and 4A1 is 
clearly co-localized with CK-19 immunofluorescence in cells surrounding the bile ducts, 
OATP5A1 staining is barely apparent in CK-19 positive cells. Representative HCC and 
MLT samples are shown in Figure 3B and C, respectively. 
OATP mRNA expression in human hepatocytes and HepG2 cells. As HepG2 
cells are a widely used model for the study of liver cancer, we also investigated the 
OATP mRNA expression pattern in this cell line (Figure 5) and compared it to that in 
human hepatocytes derived from nine human donors (Figure 4). mRNA expression of 
eight OATPs (OATP1B1, 1B3, 2A1, 2B1, 3A1, 4A1, 4C1 and 5A1) was observed in all 
hepatocyte samples and HepG2 cells. OATP1A2 was detectable in only one hepatocyte 
sample, but not in HepG2 cells. 
In hepatocytes, interindividual variations for OATP1B3, 2B1, 4C1 and 5A1 comprised a 
rather small range of 2-fold, but expression of OATP2A1, 3A1, and 4A1 mRNA varied 
considerably. Expression levels ranged from nearly undetectable to 9-fold for 
OATP2A1, 4-fold for OATP3A1 and 6-fold for OATP4A1. 
In HepG2 cells, pronounced downregulation by was seen for OATP1B1, 1B3, and 
5A1 mRNA expression compared to hepatocytes (p<0.05) (Figure 5). In addition, 
OATP2A1 and 3A1 mRNA levels were 11- and 43-fold lower, respectively, than the 
average expression in the hepatocytes. However, because of the high interindividual 
variability of these OATPs in hepatocytes (Figure 4), differences did not reach 
significance. OATP4A1 and 4C1 were the only OATPs that were expressed at higher 
levels in HepG2 cells than in human hepatocytes.  
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To investigate whether downregulation of OATP mRNA might be due to 
hypermethylation in the promoter region, we analyzed changes in OATP expression 
after the treatment of HepG2 cells with the demethylating agent Aza-dC (Figure 5). 
Expression of OATP2A1 and 5A1 mRNA was vastly increased, and their expression 
reached levels similar to that observed in hepatocytes (OATP5A1: 1.1.0±0.16 and 
OATP2A1: 2.54±1.05; Means±SEM). Interestingly, mRNA expression of OATP4A1 and 
4C1 in the HepG2 cells was decreased after Aza-dC treatment.  
91 
DISCUSSION 
We show that of the eleven human OATPs, all but OATP1C1 and OATP6A1 are 
expressed in human cancerous and non-cancerous liver samples. With the exception of 
OATP1A2, these transporters are also detectable in hepatocytes and HepG2 cells. 
However, the expression patterns differ between non-cancerous samples and HCC, 
CCC and MLT specimens. Previous data demonstrated decreased expression of 
OATP1B1 and 1B3 in benign hyperplasia and malignant hepatocellular lesions as 
compared to normal liver,18,19,24 indeed, we also show different degrees of down-
regulation of these transporters in HCC, CCC and MLT as compared to non-cancerous 
adjacent tissue. The most pronounced reduction in OATP1B1 and 1B3 mRNA 
expression was observed in CCC and may at least partly reflect replacement of 
hepatocytes by malignant cells transformed from cholangiocytes and their precursors. 
Dedifferentiation of these cells may also explain downregulation of OATP1A2, a 
transporter expressed in cholangiocytes in healthy human liver.25 
We further show that expression of OATP2A1, 3A1, 4A1 and 5A1, an OATP with an 
unknown function,1 are detectable in most non-cancerous liver specimens. This was 
also seen in isolated normal hepatocytes, although the expression of OATP5A1 was 
highly variable between individuals. High interindividual variability may also explain why 
the expression of OATP2A1, 3A1 and 4A1 was not consistently observed in all studies 
of human liver using RNA from different sources.10,11,12 
Overall, our real-time RT-PCR data clearly show that in all tumor groups, OATP2A1, 
3A1 and 5A1 are expressed at higher levels in cancer versus non-cancerous tissues. 
Furthermore, increased mRNA levels of OATP2A1 correlated with a clear membrane-
located staining of cancer cells in HCC and MLT samples. Additionally, an overlapping 
pattern with the biliary/progenitor cell marker cytokeratin 1926 was observed in CCC and 
MLT. Similar to colon cancer, the prostaglandin transporter OATP2A1 may also be 
important in the termination of prostaglandin signaling in liver cancer.27,28 In addition, 
immunofluorescent staining of OATP4A1 and 5A1 was detected on the cell membranes 
in cancerous sections. However, bile duct derived cytokeratin 19-positive cells were 
only positive for OATP4A1. This is interesting, as expression of this cytokeratin is 
associated with a poor prognosis in liver cancer.29 In addition, we observed higher 
mRNA and protein expression of OATP4A1 only in the MLT group. This may reflect up-
regulation of OATP4A1 mRNA in samples isolated from colon tumors, confirming 
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previous array data.22 This would warrant further investigations of OATP4A1 as a 
possible diagnostic marker for colon carcinoma derived MLTs. 
We further demonstrate that all OATPs expressed in hepatic tumors, except OATP1A2, 
are also present in HepG2 cells. However, expression of most OATPs was 
downregulated in the hepatoma cell line. Epigenetic silencing of OATP expression may 
be important for the regulation of the expression of some OATPs. Indeed, this was 
recently demonstrated for OATP1B3 in HepG2 cells30 and for OATP2A1 in the colon 
cancer cell lines HT-29 and LS174.28 In line with these findings, we showed that Aza-dC 
effectively restored OATP2A1 and 5A1 mRNA expression in HepG2 cells to levels 
similar to those observed in hepatocytes.  
In conclusion, we show that in contrast to the “liver-specific” OATP1B1 and 1B3, mRNA 
expression of OATP2A1 and 5A1 is upregulated in primary and secondary hepatic 
tumors. Moreover, OATP4A1 mRNA upregulation is restricted to the MLT group. The 
distinct patterns and an epigenetic regulation for individual OATPs suggest specific 
functions for these factors in tumor cells, which may involve transport of molecules 
important for cellular signaling as well as drugs used in therapy.  
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PATIENTS AND METHODS 
Patient samples. Samples of liver cancer and the adjacent non-cancerous tissue 
were obtained from patients undergoing routine surgery for liver tumors. Informed 
consent was obtained from all patients and permission for the study was obtained from 
the Ethical Committee of the Institution.  
Hospital tumor history records were used to obtain information regarding stage at 
diagnosis, tumor grade and age. The total number of tumor specimens was 22 with a 
nearly equal gender distribution of ten male (n=10) and twelve (n=12) female samples. 
Twelve of the specimens were collected from HCC (n=7), CCC (n=5) and MLT (n=10) 
patients. Eight metastases were from patients with a primary tumor in the colon with the 
remainder of the primary tumors unknown. Detailed patient characteristics are shown in 
Table 1.  
Human hepatocytes. Expression of OATPs in hepatocytes from nine individuals 
was studied using real-time RT-PCR. Two females and seven males with a mean age of 
50.9±11.8 (S.D.) years served as liver donors. Hepatocytes were isolated as described 
previously.31 
Cell culture (HepG2 cell line). The HepG2 cell line was originally obtained from 
ATCC and was maintained in phenol-red free RPMI 1640 medium (PAN Biotech, 
Aidenbach, Germany) containing 10% heat-inactivated fetal bovine serum (FBS) and 
antibiotics (100 U of penicillin/ml and 100 µg of streptomycin/ml; Invitrogen, Paisley, 
United Kingdom) in a humidified atmosphere at 37°C with 5% CO2/ 95% humidity. 
5-aza-2´-deoxycytidine (Aza-dC) treatment. HepG2 cells were seeded in 6-well 
plates. After 24 h incubation in serum-free medium, cells were treated with either 5 µM 
Aza-dC (Sigma, Deissenkirchen, Germany) dissolved in medium containing 0.1% 
DMSO or medium containing 0.1% DMSO only. After 72 h of treatment, total RNA from 
cells was isolated as described below. 
RNA extraction. Total RNA was extracted from liver tissue and cell lines using TRI 
Reagent® (Applied Biosystems, Warrington, UK) according to the manufacturer’s 
instructions. The concentration, purity, and integrity of RNA samples were determined 
by UV absorbance and electrophoresis. RNA from cancerous and non-cancerous colon 
samples was a kind gift from Dr. E. Kallay.32 
Quantitative real-time RT-PCR. We reverse transcribed 2 µg of total RNA to cDNA 
using the high capacity cDNA reverse transcription Kit (Applied Biosystems) using 
random hexamer primers as recommended by the manufacturer. We purchased 
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TaqMan® Gene Expression Assays (Applied Biosystems) for all eleven human OATPs. 
In order to evaluate the appropriate reference genes, we analyzed the expression of 12 
different human housekeeping genes in malignant and adjacent non-malignant tissue 
samples using a geNormTM housekeeping gene selection kit with PerfectProbeTM 
(PrimerDesign Ltd., South-Hampton, UK). We selected CYC1, UBC, ATP5B and 18S as 
acceptable reference genes for TaqMan® real-time analysis of the tissue samples. For 
the human hepatocytes and HepG2 cells, we tested a panel of eight housekeeping 
genes and HPRT was chosen as the acceptable reference gene. Real-time RT-PCR 
was performed in a reaction volume of 10 µl. The target gene amplification mixture 
contained 5 µl 2X TaqMan® Gene Expression PCR Master Mix, 0.5 µl of the 
appropriate Gene Expression Assay, 10 ng template cDNA diluted in 2.5 µl nuclease 
free water and 2 µl nuclease free water. Thermal cycling conditions were as follows: 2 
min at 50°C, 10 min at 95°C, 40 cycles of 15 s at 9 5°C and 1 min at 60°C. Fluorescence 
generation from TaqMan® probe cleavage by the 5’→3’ exonuclease activity of the DNA 
polymerase was measured with the StepOnePlus system (Applied Biosystems). All 
samples were amplified in duplicates. Results were imported into Microsoft Excel for 
further analysis and comparable cDNA amounts in the experimental samples were 
calculated according to Hellemans et al.33 
Real-time RT-PCR was performed with the following prefabricated TaqMan® Gene 
Expression Assays (Applied Biosystems) containing intron-spanning primers: 
OATP1A2: Hs00245360_m1, OATP1B1: Hs00272374_m1, OATP1B3: 
Hs00251986_m1, OATP1C1: Hs00213714_m1, OATP2A1: Hs00194554_m1, 
OATP2B1: Hs00200670_m1, OATP3A1: Hs00203184_m1, OATP4A1: 
Hs00249583_m1, OATP4C1: Hs00698884_m1, OATP5A1: Hs00229597_m1, 
OATP6A1: Hs00542846_m1 and the endogenous controls 18S Part # 4310893E 
(Applied Biosystems), HPRT Part # 4310890E (Applied Biosystems), CYC1, UBC and 
ATP5B (HK-DD-hu-300, Primer Design Ltd.). 
Real-time RT-PCR data analysis. Real-time RT-PCR data are presented as a heat 
map with hierarchical clustering analysis using average linkage algorithms and distance 
measures based on standard Pearson correlation (centered correlation). 
Immunofluorescence. For immunofluorescence staining, 4 µm sections were 
generated with a Cryostat-Microtome HM 500 OM (Microm, Heidelberg, Germany) from 
frozen liver samples (stored at -80°C). Tissue sect ions were fixed with acetone and 
blocking was performed with 5% BSA in PBS. Incubation with the primary antibody was 
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done overnight. Dilutions for primary antibodies were 1:100 for OATP2A1 (ab160200, 
Cayman Chemical, Ann Arbor, MI) and OATP5A1 (HPA 025062, Atlas Antibodies, 
Stockholm, Sweden), 1:20 for OATP4A1 (sc-51169, Santa Cruz Biotechnology, CA), 
and 1:500 for cytokeratin 19 (clone A53-B/A2.26, Lab Vision-Neo Markers, Fremont, 
CA, USA). After washing, sections were incubated with Alexa Fluor® IgG (Invitrogen, 
Carlsbad, CA) using the following dilutions: Alexa Fluor® 488 anti-rabbit IgG (1:2000) 
and anti-goat IgG (1:200), and Alexa Fluor® 568 anti-mouse IgG (1:1000). Cell nuclei 
were counterstained with bisbenzimide in PBS (Hoechst 33342, Sigma, Munich, 
Germany) at a 1:5000 dilution. Sections were mounted in Mowiol 4-88 (Carl Roth, 
Karlsruhe, Germany) and fluorescent staining was visualized with an Axioplan 2 
microscope (Carl Zeiss, Jena, Germany). Images were captured using an AxioCam 
HRc2 Color CCD digital camera and Axiovision 4.6 software (Carl Zeiss Vision GmbH, 
Aalen, Germany). 
Statistical analyses. Comparisons of significant differences in the expression of 
OATPs between cancerous and adjacent non-cancerous tissue specimens were 
performed using the Mann-Whitney U test. Significance was defined as p<0.05. 
OATP nomenclature. Official nomenclature differs between genes and protein using 
the terms SLCO and OATP, respectively.34 To facilitate understanding, OATP was 
usedfor both genes and proteins. 
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Table 1 Patient’s characteristics 
Sample  Gender  Age  Carcinoma type  Grade 
         
1  Male  43  HCC  3 
2  Male  54  MLT 
 
3 
3  Male  57  MLT 
 
3 
4  Male  56  MLT 
 
2 
5  Female  58  CCC  2 
6  Male  62  HCC  2 
7  Male  48  HCC  2-3 
8  Male  22  MLT† 
 
3 
9  Female  41  CCC  2 
10  Female  42  MLT 
 
2 
11  Female  16  HCC  3 
12  Female  83  CCC  3 
13  Female  74  CCC 
 
2 
14  Female  78  CCC  3 
15  Female  75  MLT† 
 
3 
16  Male  62  MLT  3 
17  Male  75  HCC  2 
18  Female  66  MLT 
 
2 
19  Female  75  MLT 
 
3 
20  Female  66  MLT 
 
3 
21  Female  77  HCC  3 
22  Male  44  HCC  2-3 
                
 
        
 
HCC, hepatocellular carcinoma; CCC, cholangiocarcinoma; 
MLT, metastatic liver tumors; †, primary tumors not 
specified 
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FIGURE LEGENDS 
Figure 1. Heatmap showing mRNA expression of all 11 human OATPs in non-
cancerous (N) and cancerous (T) liver tissue samples of 22 patients. Data 
represent upregulation (red) or downregulation (green) of OATP mRNA compared to the 
median expression level (black) of all samples.  
 
Figure 2. mRNA expression of human OATPs in different types of liver cancer 
compared to the non-cancerous controls. Data represent the logarithmic fold 
regulation of mRNA in the cancerous samples compared to the adjacent non-cancerous 
ones. Data are given as means±SEM. HCC, hepatocellular carcinoma; CCC, 
cholangiocarcinomas; MLT, metastatic liver tumors of the colon. Asterisks indicate 
statistical significance (p<0.05). 
 
Figure 3. Immunolocalization of OATP2A1, 4A1 and 5A1 in liver cancer.  
A Immunofluorescence staining of tissue sections from non-cancerous and adjacent 
cancerous sections  were probed with antibodies against OATP2A1, 4A1 and 5A1.  
(inserts without nuclei staining). Preferential green staining of plasma membranes is 
seen in the cancerous sections, only.  
B Double immunofluorescence staining of OATP2A1 and 5A1 (green) with the 
biliary/progenitor cell marker cytokeratin 19 (red) and the merged OATP/CK-19 image in 
an HCC sample. 
C Double immunofluorescence staining of OATP2A1 and 4A1 (green) with the 
biliary/progenitor cell marker cytokeratin 19 (red) and the merged OATP/CK-19 in an 
MLT sample. 
 
Figure 4. Expression of OATPs in human hepatocytes. Total RNA was isolated and 
reverse transcribed from hepatocytes prepared from livers of nine healthy individuals. 
OATP mRNA expression was then investigated by real-time RT-PCR analysis. Values 
from each of the seven analyzed hepatocyte populations are indicated. Line, mean of 
the mRNA values from the nine hepatocyte donors. 
 
Figure 5. Expression of OATP mRNAs in HepG2 cells and restoration of OATP2A1 
and 5A1 mRNA expression after Aza-dC treatment. Total RNA was isolated and 
reverse transcribed from HepG2 cells either treated with solvent (0.1% DMSO) or with 5 
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µM 5-Aza-2’-deoxycytidine for 72 h. mRNA expression levels of individual OATPs are 
given as the logarithmic fold regulation of mRNA in the HepG2 cells compared to the 
human hepatocytes. Data are given as means±SEMs. 
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Abstract  
 
Paclitaxel is an anti-tumour agent used for the treatment of ovarian cancer with 
pronounced tumour accumulation. The diverse pharmacokinetics and variable efficacy 
of this substance are attributable to the fact that several ATP-binding cassette 
transporters are involved in the cellular efflux of the compound. To investigate whether 
organic anion transporter polypeptides (OATPs) may also act as cellular carriers for 
paclitaxel, we studied the mRNA expression of all known human OATPs in the two 
ovarian carcinoma cell lines OVCAR-3 and SK-OV-3. TaqMan® real-time RT-PCR 
analysis revealed expression of several OATPs in both cell lines with the highest mRNA 
levels for OATP1B1 and 1B3 in the SK-OV-3 cells, which was correlated with higher 
intracellular paclitaxel concentration in this cell line. Further studies using cRNA 
microinjected Xenopus laevis oocytes revealed OATP1B1 and OATP1B3 as high affinity 
transporters of paclitaxel with apparent Km values of 0.6 µM and 1.6 µM, respectively. 
Therefore, OATB1B1 and OATP1B3 may play a key role in the uptake of paclitaxel into 
ovarian cancer cells during therapy. 
 
Keywords: Ovarian cancer, paclitaxel, OATPs, PCR, SK-OV-3, OVCAR-3  
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1. Introduction 
Ovarian cancer is often diagnosed at an advanced stage because early symptoms are 
inconspicuous and reliable diagnostic biomarkers are not available [1]. This contributes 
to a poor 5-year overall survival rate (< 40%) and a high death rate [2]. After initial 
surgery on the tumour, a combination of paclitaxel together with platinum derivatives is 
applied in standard chemotherapy [3]. Although high response rates to this initial 
regimen are observed, a relapse is seen in two-thirds of patients due to the rapid 
development of drug resistance [4, 5], which is often caused by a reduced accumulation 
of the drug in cancer cells.  
It is well-established that overexpression of ATP-powered efflux pumps such as P-
glycoprotein (P-gp) or MDR1 coded by the ABCB1 gene induces drug resistance for 
cytotoxic agents, including paclitaxel [6]. Indeed, taxane resistance due to 
overexpression of P-glycoprotein (MDR1) has been shown in ovarian cancer [7]. 
Furthermore, overexpression of the multidrug-resistance-related proteins MRP2 
(ABCC2), MRP3 (ABCC3) and MRP7 (ABCC10) have been identified as paclitaxel-
resistance factors in various cell lines and tumour tissues, including HER-2-amplified 
breast carcinoma and non-small-cell lung cancer [8, 9, 10]. However, uptake 
mechanisms into tumour cells might be even more important for the efficacy of 
anticancer drugs because they are important determinants for intracellular drug 
concentration [11].  
One of the most important cellular drug uptake mechanisms in humans is via 
members of the organic anion transporting polypeptide family (OATP) [12, 13]. Official 
nomenclature differentiates between genes and protein using the term “SLCO” and 
“OATP”, respectively [14]. To facilitate readability and understanding of the manuscript, 
“OATP” is used for both genes and proteins. OATPs are expressed in a variety of 
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tissues [15] and tumours [16, 17] mediating the transport of endogenous and 
exogenous compounds and clinically used drugs [12, 13, 18]. Studies have shown that 
uptake transporters can confer sensitivity to anticancer agents [19, 20, 21, 22, 23, 24] 
as shown for the OATP1B3 substrate methotrexate [19]. This may be important for 
therapy because expression of OATP greatly varies in tumour cell lines [25].  
 Cellular uptake of paclitaxel is known to be facilitated by OATP1B3 at least in 
Xenopus laevis oocytes [26] and by the organic anion transporter 2 (OAT2; gene 
symbol: SLC22A7) [27] expressed predominantly in human liver and kidney [28]. 
However, whether OAT2 is also expressed in human cancer cells is unknown. As 
OATPs exhibit overlapping substrate specificity, we hypothesised that additional OATPs 
may also contribute to the uptake of paclitaxel. To gain further insight into the possible 
role of OATP transporters in ovarian cancer, we characterised the mRNA expression 
profiles of all 11 known transporters and studied the uptake of paclitaxel in the estrogen 
responsive OVCAR-3 [29] and the estrogen-independent SK-OV-3 [30] ovarian cancer 
cell lines. Moreover, we investigated the specific paclitaxel transport activity of all 11 
known OATPs by injecting X. laevis oocytes with their corresponding cRNA. Our results 
demonstrated that paclitaxel uptake in OVCAR-3 and SK-OV-3 cells correlates with 
OATP1B1 and OATP1B3 mRNA expression, indicating an important role of these 
transporters in tumour therapy.  
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2. Material and Methods 
 
2.1. Materials 
[3H]paclitaxel (740 GBq/mmol) was purchased from American Radiolabelled Chemicals 
(St. Louis, MO). The ovarian carcinoma cell lines OVCAR-3 and SK-OV-3 were 
obtained from the ATCC (Manassas, VA). Foetal Calf Serum (FCS) was obtained from 
Invitrogen (Carlsbad, CA). The ovarian carcinoma cell lines were maintained in phenol-
red-free RPMI-1640 medium supplemented with L-glutamine (PAN-Biotech GmbH, 
Aidenbach, Germany), 10% FCS and 1% penicillin (10.000 U/ml)/streptomycin (10 
mg/ml) solution (Invitrogen) in a humidified atmosphere at 37 °C with 5% CO 2.  
 
2.2. TaqMan® real-time RT-PCR 
Total RNA from OVCAR-3 and SK-OV-3 cancer cells was isolated using the RNeasy® 
Mini kit (Qiagen, Hilden, Germany), and the RNA was treated with RNase free DNase 
(Qiagen) to remove possible genomic DNA. The concentration, purity and integrity of 
RNA samples were determined on a Nanodrop ND-1000 (Kisker-Biotech, Steinfurt, 
Germany) and agarose gel electrophoresis. A total of 1 µg of total RNA was reverse 
transcribed in 20 µl reactions using the High Capacity cDNA RT kit (Applied 
Biosystems, Foster City, CA) with the provided random hexamer primers and RNase 
inhibitor (Applied Biosystems) according to the manufacturer’s instructions. TaqMan® 
Gene Expression Assays (Applied Biosystems) were purchased for all 11 human 
OATPs and four transporters from the ABC family (Table 1). Control assays for the 
ACTB (PN 4326315E) and HPRT (PN 4310890E) genes were also purchased from 
Applied Biosystems. Prefabricated primers and probes for the endogenous control 
genes GAPDH and RPL13A were obtained from PrimerDesign (PrimerDesign Ltd., 
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Southampton, UK). TaqMan® real-time RT-PCR was performed in an amplification 
mixture volume of 10 µl containing 5 µl 2x TaqMan® Gene Expression PCR Master Mix                                                                                                                                        
(Applied Biosystems), 0.5 µl of the appropriate Gene Expression Assay, 10 ng template 
cDNA diluted in 4 µl nuclease free water, and 0.5 µl nuclease free water. Thermal 
cycling conditions were 2 min at 50 °C and 10 min a t 95 °C, followed by 40 cycles of 15 
s at 95 °C and 1 min at 60 °C on the 7900HT Sequenc e Detection System (Applied 
Biosystems) equipped with a 96-well fast cycling block. Results were imported into 
DataAssist™ 2.0 software (Applied Biosystems) for automated data analysis using the 
comparative Ct (∆∆Ct) method [31]. Thus, a normalisation factor (NF) was calculated by 
averaging the Ct values of the four endogenous control genes ACTB, GAPDH, HPRT, 
and RPL13A via the geometric mean. Relative quantities (RQ) for every sample were 
then calculated by the formula RQ = 2 (–∆Ct) / 2(–∆Ctreference), where ∆Ct = Average Ct – NF. 
The standard deviation (SD) was calculated for Ct values of the technical replicates and 
was used to calculate the RQMin and RQMax:  
RQMin = 2(–∆Ct – SD) / 2(–∆Ctreference)  
RQMax = 2(–∆Ct + SD) / 2(–∆Ctreference)  
according to the DataAssist™ v2.0 Software User Instructions (Applied Biosystems). 
 
2.3. Transport experiments in cell lines  
Cells that were 80-90% confluent were washed three times and incubated for 15 min 
(37 °C) in 12-well plates with 1 ml Krebs-Henseleit  buffer (KHB, 118 mM NaCl, 23.8 mM 
NaHCO3, 4.8 mM KCl, 1.0 mM KH2PO4, 1.2 mM MgSO4, 12.5 mM HEPES, 5.0 mM 
glucose, and 1.5 mM CaCl2, pH 7.4) [32]. Subsequently, cells were treated with 1 
ml/well KHB containing 18.5 nM [3H]paclitaxel. Unlabelled paclitaxel was added to a 
final concentration of 5 µM. Uptake was measured after 1, 2, 4, 6 and 10 min or, 
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alternatively, at graded concentrations (0.5, 1.0, 2.5, 5.0 and 10.0 µM paclitaxel) after 1 
min of incubation, which had been determined to be within the linear range of uptake. 
Control studies were performed at 4 °C to determine  temperature-insensitive paclitaxel 
accumulation. Paclitaxel transport was stopped by adding ice-cold KHB, followed by 
three washes. The amount of paclitaxel in the cells was determined by first adding 300 
µl 0.2 N NaOH to each well. After 12 h at 4 °C, 150  µl 0.4 N HCl and 4 ml Emulsifier-
Safe™ scintillation cocktail (PerkinElmer) were added, and [3H]paclitaxel was measured 
in an LS6500 scintillation counter (Beckman Coulter, Fullerton, CA). Protein 
determination was performed using a BCA™ Protein Assay (Pierce, Rockford, IL) with 
bovine serum albumin as the standard. 
 
2.4. Cytotoxicity assay 
A total of 1000 cells/well were seeded on 96-well plates. After 48 h, cells were treated 
with graded concentrations of paclitaxel (0.5, 1.0, 2.0, 4.0, 6.0, 10.0 and 50.0 nM) or 
0.1% solvent dimethyl-sulfoxide alone. Viability was measured after 48 h using the 
CellTiter-Glo® Assay (Promega, Madison, WI) and a Victor™ microplate reader 
(PerkinElmer, Waltham, MA). Corresponding IC50 values were calculated by non-linear 
regression analysis using GraphPad Prism 5 software (GraphPad, La Jolla, CA). 
 
2.5. Preparation of OATP cDNA for the expression in X. laevis oocytes 
The plasmids containing the human full-length cDNA from OATP1B1 (pSPORT1) and 
OATP1B3 (pSPORT1) were originally cloned from a human liver cDNA library, and 
OATP2B1 (pCMV6-XL4) was cloned from a human brain cDNA library [33]. OATP1A2 
(pDRIVE, IHS1382-8428120), OATP2A1 (pOTB7, EHS1001-6793541), and OATP4C1 
(pENTR223.1, OHS4559-99620240) full-length cDNA clones were purchased from 
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Open Biosystems (Thermo Fisher Scientific, Huntsville, AL). The lacking stop codon in 
the OATP4C1 clone was reconstructed by PCR using 0.5 mM dNTPs, 12.5 pmol of 
each primer, 0.5 U Hot Start Phusion® DNA polymerase (Finnzymes, Espoo, FI) and 1x 
HF buffer (Finnzymes) in a final volume of 25 µl. The following primer sequences were 
used (start codon in bold): forward: 5’-CC ACC ATG AAG AGC GC-3’ and reverse: 5’-
TCA CCC TTC TTT TAC TAT TTT GTT G-3’. Thermal cycling conditions were 98 °C for 
30 s, followed by 25 cycles of 98 °C for 10 s, 62 ° C for 20 s, and 72 °C for 1 min on a 
MyCycler™ (Bio-Rad, Hercules, CA). The obtained full-length OATP4C1 PCR fragment 
was subcloned into the pJET1.2 vector (Fermentas, St.Leon-Rot, Germany) using blunt-
end cloning and the CloneJET PCR cloning kit (Fermentas) according to the 
manufacturer’s instructions. OATP1C1 (pBluescriptR, IRAKp961I0832Q) and OATP4A1 
(pOTB7, IRALp962P0734Q) plasmids were purchased from Imagenes (Berlin, 
Germany). To obtain full-length cDNA sequences of OATP3A1 and OATP5A1 we 
purchased total RNA from normal human ovary (MVP™, Stratagene, La Jolla, CA). 
Total testis RNA (Clontech Laboratories, Inc., Mountain View, CA) for the cloning of 
OATP6A1 was donated  by Dr. D. Mechtcheriakova (Department of Pathophysiology, 
Medical University of Vienna, Austria). Reverse transcription was performed by 
preincubation of 0.4 µg total RNA with 0.5 µg oligo(dT) primers in a volume of 11 µl for 5 
min at 65 °C. Subsequently, 9 µl of reverse transcr iption master mix was added, 
containing 0.5 mM of dNTPs (Fermentas), 20 U of RNaseOUT™ (Invitrogen, Carlsbad, 
CA), 200 U of RevertAid™ H Minus M-MuLV reverse transcriptase (Fermentas) and 1x 
reaction buffer in a final volume of 20 µl and incubation at 45 °C for 1 h, followed by 70 
°C for 10 min. The sequence of OATP6A1 was amplifie d from 50 ng of testis cDNA and 
the sequence of OATP3A1 and OATP5A1 from 50 ng of ovary cDNA using 0.5 mM of 
dNTPs, 12.5 pmol of each primer, 0.75 µl DMSO, 0.5 U Hot Start Phusion® DNA 
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polymerase (Finnzymes, Espoo, FI) and 1x GC buffer (Finnzymes) in a final volume of 
25 µl. Primer sequences were the following (start codons are in bold): OATP3A1, 
forward: 5’-A AGG ATG CAG GGG AAG AAG C-3’, reverse: 5’-GCC CTC CTT TAG 
TCA CTA TAA AAC GG-3’; OATP5A1, forward: 5’-TGA ATT CTA AGC GCC ATG GAC 
GAA-3’, reverse: 5’-TCT TCC ATT TTC AAG CTT CAG GAG G-3’; and OATP6A1, 
forward: 5’-A GCC ATG TTC GTA GGC GTC GC-3’, reverse: 5’- ATC ACA ATG ATG 
ATC CAG TTA CAA GTC AG-3’. PCR conditions for OATP3A1 were 98 °C for 30 s, 
followed by 40 cycles of 98 °C for 10 s, 68.5 °C fo r 20 s and 72 °C for 1 min on a Bio-
Rad MyCycler™. The conditions for OATP5A1 and OATP6A1 were identical except for 
annealing at 66 °C. The purified cDNA was then clon ed into the pJET1.2 vector using 
the CloneJET PCR cloning kit (Fermentas). Sequences of OATP3A1, 5A1 and 6A1 
were checked by forward and reverse full-length sequencing (MWG, Ebersberg, 
Germany), and compared to the appropriate reference sequences (OATP3A1 transcript 
variant 1: NM_013272.3; OATP5A1: NM_030958.1; OATP6A1: NM_173488.3). In 
OATP3A1, we found a polymorphism for 1083G>C, resulting in the amino acid 
exchange of Glu294Asp. For OATP5A1, we determined an SNP at 1406C>G affecting 
the amino acid exchange of Leu264Val. No polymorphisms were found in OATP6A1. 
 
2.6. Linearisation, template preparation, and in vitro transcription of OATP cRNA 
All plasmid inserts were verified for correct sequence and orientation by sequencing 
(MWG). For the in vitro synthesis of cRNA, the cDNA clone of OATP4A1 was linearised 
with BglII, and Mlul was used for the linearisation of OATP1B1 and OATP1B3 plasmids. 
For OATP3A1, OATP4C1, OATP5A1, and OATP6A1 we used XbaI for linearisation. 
OATP1C1 was linearised with Acc65I and OATP2A1 with DraI. All restriction enzymes 
were obtained from Fermentas. After linearisation, proteinase K and 0.5% SDS 
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treatment, plasmid DNA was purified by phenol/chloroform extraction and ethanol 
precipitation. OATP1A2 and OATP2B1 sequences were amplified from plasmid using 
0.5 mM of dNTPs, 12.5 pmol of each primer, 0.75 µl DMSO, 0.5 U Hot Start Phusion® 
DNA polymerase (Finnzymes) and 1x GC buffer (Finnzymes) in a final volume of 25 µl. 
Standard vector primers (M13) were used for amplification: forward: 5’- TGT AAA ACG 
ACG GCC AGT-3’ and reverse: 5’- CAG GAA ACA GCT ATG ACC-3’. Thermal cycling 
conditions were as follows: 98 °C for 30 s, 25 cycl es of 98 °C for 15 s, 55 °C for 20 s, 
and 72 °C for 1 min on a Bio-Rad MyCycler™. The obt ained OATP1A2 and OATP2B1 
PCR products were gel-purified and used as templates for in vitro transcription. 5’ 
capped cRNAs were transcribed in vitro using 1 µg of template DNA and either T7 or 
SP6 mMESSAGE mMACHINE® kit (Ambion, Austin, TX) according to the 
manufacturer’s instructions. Subsequently, the cRNAs were polyA-tailed using the polyA 
tailing kit (Ambion) according to the protocol. The polyA cRNA was then purified using 
the MEGAClear™ kit (Ambion). The concentration, purity, and integrity of cRNA 
samples were determined on a Nanodrop ND-1000 (Kisker-Biotech) and by denaturing 
gel electrophoresis. 
 
2.7. Paclitaxel transport studies in Xenopus laevis oocytes 
Preparation of stage V-VI oocytes from X. laevis was performed as previously described 
[34]. Briefly, X. laevis frogs (NASCO, USA) were anaesthetised by exposing them for 15 
min to a 0.2% solution of MS-222 (methane sulfonate salt of 3-aminobenzoic acid ethyl 
ester; Sandoz Company) before surgical removal of parts of the ovaries. Follicle 
membranes from isolated oocytes were enzymatically digested with 2 mg/ml 
collagenase (Type 1A, Sigma). One day after isolation, the oocytes were injected with 
10-50 nl of water either alone, to determine non-specific uptake of paclitaxel, or 
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containing approximately 200 ng/µl cRNA of each OATP. Injected oocytes were 
incubated in ND96 buffer (90 mM NaCl, 1 mM KCl, 1 mM MgCl2, 1 mM CaCl2, and 5 
mM HEPES, pH adjusted to 7.4, supplemented with 100 U/ml penicillin and 100 µg/ml 
streptomycin) at 18 °C for 48 hours before performi ng transport experiments with buffer 
exchange every day. Uptake studies were carried out in single oocytes using at least 12 
oocytes per data point. Oocytes were washed three times with 3 ml substrate-free 
uptake buffer (100 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 10 mM HEPES, pH 
adjusted to 7.4 with TRIS) and incubated with 400 µl uptake buffer containing 20 nM 
[³H]paclitaxel and 1% ethanol at room temperature for the appropriate time points. To 
avoid unspecific binding of [³H]paclitaxel to the surfaces of laboratory plastic wares, all 
solutions containing [³H]paclitaxel were manipulated using glass ware. For kinetic 
analysis, the uptake of radiolabelled paclitaxel was measured over a range of 
concentrations from 20 to 1180 nM using 60 min incubations, which had been 
determined to be within the linear component of uptake. Uptake was corrected for non-
specific influx using water-injected oocytes from the same batch in each experiment. 
Uptake was stopped by the addition of 3 ml ice-cold uptake buffer, and oocytes were 
washed three times with buffer before being placed in scintillation vials for dissolution 
with 10% SDS overnight. Radioactivity was measured in a liquid scintillation counter 
(LS-6500; Beckman, California, USA). 
 
2.8. Western blot analysis of OATP1B1 and 1B3 in X. laevis oocytes 
Oocyte protein expression and membrane localisation of human OATP1B1 and 1B3 
were confirmed by western blot using membrane and cytosolic protein fractions from 
OATP1B1- and 1B3-injected oocytes prepared according to Bianchi and Driscoll [35]. A 
total of 10 µg of protein was separated on 10% separating gels, blotted on PVDF 
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membranes and probed using an antibody against OATP1B1/1B3 (#BM5541, Acris, 
Herford, Germany), diluted 1:250 in TBS-T (20 mM Tris, 145 mM NaCl, 0.05% Tween 
20, pH 7.6) containing 5% milk powder [36]. On control blots, an antibody to α-tubulin 
(Sigma, T-5168) was diluted 1:8000 in TBS-T containing 5% milk powder. The HRP-
conjugated secondary antibody (#315-036-003, Jackson ImmunoResearch, Suffolk, UK) 
was used at a dilution of 1:10000 in TBS-T.  
 
2.9. Data analysis 
For kinetic analysis, data were fitted to the Michaelis-Menten (hyperbolic) model. Kinetic 
parameters were estimated using Prism 5 software (GraphPad) for Michaelis-Menten 
kinetics: 
     V=Vmax·S/(Km+S)      
Where V is the rate of reaction, Vmax is the maximum velocity, Km is the Michaelis 
constant, and S is the substrate concentration. Unless otherwise indicated, values are 
expressed as means ± SD of at least 12 individual oocytes per data point. Statistical 
differences from control values were evaluated using a Students’ t-test, and the level of 
statistical significance was set at P < 0.05. 
 
3. Results 
3.1. mRNA expression of OATPs and OAT2 in ovarian cancer cells  
To assess the role of OATP transporters for paclitaxel uptake, we investigated the 
mRNA expression of all 11 human OATPs in the human ovarian carcinoma cell lines 
OVCAR-3 and SK-OV-3. Interestingly, expression of the liver-specific OATP1B3 was up 
to 204-fold higher in SK-OV-3 cells compared to OVCAR-3 cells (Table 2). Even more 
pronounced was the difference for OATP1B1 expression, as this transporter was only 
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found in SK-OV-3 cells. Furthermore, a different expression pattern was also observed 
for OATP2B1, which was 71-fold higher in SK-OV-3 cells, and for OATP5A1, which was 
85-fold higher in the OVCAR-3 cell line. OATP mRNA of 1A2, 2A1, 3A1, 4A1, 4C1, 
could be detected in OVCAR-3 and SK-OV-3, although the observed distribution was 
more balanced. Expression of OATP1C1, OATP6A1, and OAT2 mRNA was below the 
detection limit in both cell lines.  
 
3.2. Transport of paclitaxel in ovarian cancer cell lines 
Based on the different expression of OATPs in OVCAR-3 and SK-OV-3 cells, we also 
expected altered intracellular paclitaxel levels. In both cell lines, uptake of paclitaxel was 
linear with time, up to 90 sec, and with respect to 5 µM paclitaxel concentrations (data 
not shown). For kinetic analysis, an incubation time of 1 min was therefore chosen, 
showing a typical Michaelis-Menten kinetic for the uptake of paclitaxel into the OVCAR-
3 cells with a Vmax of 517.5 ± 86.2 pmol/mg protein/min and a Km value of 17.2 ± 4.1 µM 
(Fig. 1A). However, transport of paclitaxel into the SK-OV-3 cell line was far more 
pronounced, showing an uptake rate of 1660 ± 126 pmol/mg protein/min at a 
concentration of 10 µM. Based on the limited solubility of this drug in serum-containing 
cell culture medium, saturation kinetics could not be observed (Fig. 1B)  
 
3.3. Paclitaxel transport studies in X. laevis oocytes 
To investigate whether other OATPs besides OATP1B3 contribute to paclitaxel uptake 
into OVCAR-3 and SK-OV-3 cells, uptake studies were performed for all 11 known 
human OATPs in X. laevis oocytes injected with cRNA coding for each of the OATP 
family members. Using radiolabelled paclitaxel (20 nM for 60 min), uptake in OATP1B1- 
and 1B3-expressing oocytes was significantly higher compared to the water control 
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(5.3- and  3.9-fold, respectively; P < 0.0001), while no other OATP favoured paclitaxel 
uptake (Fig. 2). The time course of [³H]paclitaxel uptake by OATP1B1- and 1B3-
expressing oocytes was linear with time for up to 60 min (Figs. 3A and B). The kinetic 
constants for this uptake revealed saturable transport in OATP1B1-expressing oocytes, 
with a Vmax of 12.3 ± 0.4 fmol/oocyte/min and a Km value of 0.6 ± 0.04 µM. OATP1B3-
injected oocytes showed a 2.4-fold higher Vmax for paclitaxel (30 ± 1.6 fmol/oocyte/min) 
and a 2.7-fold higher KM value of 1.6 ± 0.13 µM compared to OATP1B1 (Figs. 3C and 
D). OATP1B1 and 1B3 protein expression in X. laevis oocytes was also confirmed by 
western blot analysis (see Figs. 3E and F). 
 
3.4. Paclitaxel cytotoxicity 
Despite differences in uptake kinetics, both ovarian carcinoma cell lines showed a 
similar sensitivity to paclitaxel. After treatment of cells with various concentrations of 
paclitaxel for 48 h, an IC50 of 3.05 ± 1.18 and 4.63 ± 1.08 nM was observed for OVCAR-
3 and SK-OV-3 cell lines, respectively (Figs. 4A and B). 
 
3.5. Expression of paclitaxel efflux transporters in ovarian cancer cell lines 
Given that differences in the expression of OATP1B3 and 1B1 between the two cell 
lines did not correlate with the observed similar paclitaxel cytotoxicity, we further 
investigated the expression of four major paclitaxel efflux transporters in these two cells 
lines. We observed up to 18-fold higher mRNA expression levels for MRP2 and MRP3 
in SK-OV-3 cells (Table 3), indicating a higher efflux of paclitaxel out of the cytoplasm 
into the cellular supernatant. MDR1 and MRP7 were approximately similar in distribution 
between the two cell lines.  
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4. Discussion 
In the present study, we investigated OATPs and their correlation with paclitaxel uptake 
in the two ovarian cancer cell lines OVCAR-3 and SK-OV-3 and in cRNA-microinjected 
Xenopus laevis oocytes.  
By investigation of all 11 known OATPs by TaqMan® real-time RT-PCR, we found 
that OATP1B1, 1B3 and 2B1 were far more significantly expressed in SK-OV-3 cells, 
whereas OATP1A2, 4C1 and 5A1 were primarily present in OVCAR-3 cells. The two 
transporters OATP1C1 and OATP6A1 were not detectable in either cell line. It should 
be noted that expression of OAT2, which was previously shown to mediate the uptake 
of paclitaxel in X. laevis oocytes, was below the detection limit in both cell lines. Our 
data are consistent with the previous work of Okabe and coworkers, who also showed 
similar differences of OATP expression in OVCAR-3 and SK-OV-3 cells [25]. However, 
contrary to their study, we were unable to confirm expression of OATP6A1 in the 
OVCAR-3 cell line.  
 Based on these differences in OATP expression, we further investigated the 
concentration-dependent uptake of paclitaxel in these two cell lines. Indeed, SK-OV-3 
cells showed about 3-fold higher uptake rates at 10 µM paclitaxel (1660 ± 126 pmol/mg 
protein/min) compared to OVCAR-3 cells (518 ± 86 pmol/mg protein/min). Differences 
between the two cell lines were also seen in the uptake kinetics. Whereas paclitaxel 
uptake was linear in SK-OV-3 cells, uptake in OVCAR-3 cells followed classical 
Michaelis-Menten kinetics with a KM value of 17.25 ± 4.12 µM.  
 To date, only OATP1B3 has been confirmed as a high-affinity paclitaxel 
transporter [26] within the OATP family. Furthermore, uptake of paclitaxel was 
significantly reduced in the OATP1B3 expressing cell line HepG2 but not in OATP1B3-
deficient PR-HepG2 cells by the OATP1B3 substrate and inhibitor bromosulfophtalein 
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[37]. By systematically investigating the transport properties of paclitaxel for all 11 
OATPs using the X. laevis oocytes expression system, we were able to identify 
OATP1B1 as an additional uptake protein for paclitaxel. Indirect involvement of 
OATP1B1 in taxane transport has been reported earlier by Gui et al., who showed 
inhibition of the OATP1B1 substrate estradiol-17β-glucuronide by paclitaxel in stable 
transfected CHO cells [38]. An involvement of OATP1B1 in hepatic clearance of 
paclitaxel may explain the finding of a pharmacogenetic investigation of variants of the 
SLCO1B3 gene. In the study of Smith et al. [39], differences of paclitaxel 
pharmacokinetics did not associate with different OATP1B3 variants, one of which has 
recently been shown to influence the pharmacokinetics of mycophenolate [40].  
 The far higher uptake rates of paclitaxel in SK-OV-3 cells prompted us to 
hypothesise that this could correlate with cytotoxicity. However, paclitaxel inhibited the 
growth of OVCAR-3 and SK-OV-3 cells with comparable IC50 values (3.1 nM and 4.6 
nM), indicating that increased paclitaxel uptake in SK-OV-3 cells might be counteracted 
by efflux mechanisms. Several ABC transporters have been shown to successfully 
extrude paclitaxel from the cells. Importantly, it has been demonstrated that MDR1 and 
MRP2 as well as MRP3 and MRP7 mediate paclitaxel transport [7, 8, 9, 10]. By using 
TaqMan® real-time RT-PCR, we identified higher expression levels of MRP2 and MRP3 
in SK-OV-3 cells, whereas differences of MDR1 and MRP7 mRNA expression were 
moderate. MRP2 and MRP3 may therefore facilitate increased efflux of paclitaxel in SK-
OV-3 cells.  
 Our data suggest that, in addition to OATP1B3, OATP1B1 might be an even 
more important determinant of paclitaxel uptake in ovarian cancer cells based on its 
lower Km value in X. laevis oocytes (0.6 µm vs. 1.6 µM), which is in the range of the 
mean plasma concentration in patients (0.85 ± 0.21 µM) after 24 h of infusion [41]. 
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OATP1B1- and 1B3-mediated paclitaxel transport is of clinical importance, as both 
transporters share a wide, overlapping substrate spectrum that includes HMG-CoA 
reductase inhibitors such as fluvastatin and pitavastatin, the antibiotic rifampicin, and 
the endothelin receptor antagonist BQ123 [42]. The hepatic uptake rate of both 
transporters might be reduced by drug competition, thus resulting in increased blood 
levels. Therefore, inter-individual expression levels of OATP1B1 and 1B3 in the 
basolateral membrane of hepatocytes might be responsible for differences in the 
occurrence of toxic side effects such as neutropenia, neuropathy and cardiac effects 
during paclitaxel therapy. Such drug-drug interactions have been reported for the 
OATP1B1 and 1B3 substrates pravastatine and bosentan [43, 44] when concomitantly 
administered with clarithromycin and cyclosporine or rifampicin, respectively.  
 In conclusion, we found that OATP1B1 and 1B3 are high affinity and active 
paclitaxel transporters in transfected X. laevis oocytes, which may also be true for the 
uptake of this compound in human liver and ovarian cancer cells.   
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Table 1 
    
Overview of the applied gene expression assays (ABI) used for real time RT-PCR analysis 
Protein 
name Assay IDa            Context sequence (5'→3') 
Accession                                 
number 
     
OATP1A2 hs00245360_m1 ACCACCTTCAGATACATCTACCTCG NM_134431.2 
NM_021094.2 
OATP1B1 hs00272374_m1 ATTCCACATCATTTTCAAGGGTCTA NM_006446.3 
OATP1B3 hs00251986_m1 CTAACTTTTTGTTGGGAATCATAAC NM_019844.2 
OATP1C1 hs00213714_m1 CTCCTACCAAGGAACCAAACCTGTC NM_017435.3 
OATP2A1 hs00194554_m1 GCGCTTGCTGGCCTGGCTGCCATCT NM_005630.1 
OATP2B1 hs00200670_m1 CTGCCAGGAAGGGCAAGGACTCTCC NM_007256.2 
OATP3A1 hs00203184_m1 CTCCTCGCTCTATATAGGAATCCTG NM_013272.2 
OATP4A1 hs00249583_m1 CAGAGACCTGCCTCTCTCCATCTGG NM_016354.3 
OATP4C1 hs00698884_m1 TGGGAGAAAGCACTGATGTCACTGA NM_180991.4 
OATP5A1 hs00229597_m1 TCATTGGAAACTGGTGGAGTGGATT NM_030958.1 
OATP6A1 hs00542846_m1 CTACACTTGCAGGACTTGTTTTAAT NM_173488.3 
OAT2 hs00198527_m1 AGCCTCTGGTGGGTGCCTGAGTCTG NM_153320.2 
NM_006672.3                      
MDR1 hs00184500_m1 AGACATGACCAGGTATGCCTATTAT NM_000927.3 
MRP2 hs00166123_m1 CACCTCCAACAGGTGGCTTGCAATT NM_000392.3 
MRP3 hs00358656_m1 CAGCTGCTCAGCATCCTGATCAGGT NM_001144070.1 
NM_003786.3 
MRP7 hs00375716_m1 CCCAGCTCAGATCCCAGTTGGCTAT NM_033450.2 
aApplied Biosystems    
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Table 2 
       
Expression levels of OATP mRNA in ovarian cancer cell linesa 
Protein 
name 
OVCAR-3   SK-OV-3 
 
       
 
RQ RQ-RQMin RQMax-RQ  RQ RQ-RQMin RQMax-RQ 
 
       
OATP1A2 1.00 0.1 0.06  0.07 0.00 0.00 
OATP1B1 ND ND ND  1.00 0.01 0.01 
OATP1B3 1.00 0.00 0.00  203.93 6.87 7.11 
OATP1C1 ND ND ND  ND ND ND 
OATP2A1 1.00 0.08 0.09  0.45 0.04 0.05 
OATP2B1 1.00 0.00 0.00  70.57 0.99 1.01 
OATP3A1 1.00 0.05 0.05  0.18 0.00 0.00 
OATP4A1 1.00 0.03 0.03  6.29 0.05 0.05 
OATP4C1 1.00 0.02 0.03  0.07 0.00 0.00 
OATP5A1 1.00 0.00 0.00  0.01 0.00 0.00 
OATP6A1 ND ND ND  ND ND ND 
 
amRNA expression levels relative to OVCAR-3; Maximum values are in bold; ND, 
transcripts were below the detection limit 
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Table 3 
       
Expression levels of ABC transporter mRNA in ovarian cancer cell linesa 
Protein 
name 
OVCAR-3   SK-OV-3 
 
       
 
RQ RQ-RQMin RQMax-RQ  RQ RQ-RQMin RQMax-RQ 
 
       
MDR1 1.00 0.00 0.00  1.73 0.02 0.02 
MRP2 1.00 0.01 0.01  18.31 1.15 1.23 
MRP3 1.00 0.04 0.05  5.30 0.28 0.29 
MRP7 1.00 0.01 0.02  0.93 0.00 0.00 
 
amRNA expression levels relative to OVCAR-3; Maximum values are in bold; ND, 
transcripts were below the detection limit 
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Legends to the Figures  
 
Figure 1: Time- and concentration-dependent uptake of paclitaxel in the ovarian cancer 
cell lines OVCAR-3 and SK-OV-3. The time-dependent uptake of 5 µM paclitaxel was 
measured in OVCAR-3 (A) and SK-OV-3 (B) cells at 1, 2, 4, 6, and 10 min. 
Concentration-dependent paclitaxel uptake for OVCAR-3 (C) and SK-OV-3 (D) cells 
was evaluated after an incubation time of 1 min at 37 °C with paclitaxel concentrations 
ranging from 0.5 to 10 µM. Uptake values were corrected (net values; dotted line) for 
temperature-insensitive paclitaxel accumulation measured at 4 °C after 1 min of 
incubation for each concentration (dashed line). Kinetic constants were calculated by 
non-linear least-square analysis. Data represent the mean ± SD of triplicate 
determinations. 
 
Figure 2: Paclitaxel uptake in X. laevis oocytes. The uptake of [³H]paclitaxel was 
measured in X. laevis oocytes injected with human OATP cRNA after 60-min incubation 
with 20 nM [³H]paclitaxel. Data are given as percent of controls ± SD of at least 12 
oocytes per data point. OATPs showing significantly higher (***P < 0.001) uptake rates 
compared to water-injected oocytes (control) are marked with asterisks. 
 
Figure 3: Time course and concentration-dependent uptake of paclitaxel by OATP1B1- 
and OATP1B3-expressing X. laevis oocytes. The time-dependent uptake of 20 nM 
[³H]paclitaxel was measured for OATP1B1 (A) and OATP1B3 (B) cRNA-injected 
oocytes. Water-injected X. laevis oocytes were included as a negative control. 
Concentration-dependent paclitaxel uptake for OATP1B1- (C) and OATP1B3- 
expressing oocytes (D) was evaluated after an incubation time of 60 min with various 
 138 
paclitaxel concentrations ranging from 20 to 1180 nM. Data represent the mean ± SD of 
triplicate determinations. Protein expression of OATP1B1 (E) and 1B3 (F) in X. laevis 
oocytes was confirmed by western blot analysis of cRNA injected (+) and water injected 
(-) oocytes. 
 
Figure 4: Cytotoxic effect of paclitaxel. An ATP-based detection assay was used to 
assess paclitaxel cytotoxicity in OVCAR-3 (A) and SK-OV-3 (B) cells. Eight 
measurements were performed for each dilution point (mean ± SD). 
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Fig. 1.  
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Fig. 2.  
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Fig. 3 
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Fig. 4.  
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